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ABSTRACT
THE PYRETHROID DELTAMETHRIN WHICH CAUSES CHOREOATHETOSIS
WITH SALIVATION (CS-SYNDROME) ENHANCES CALCIUM ION INFLUX VIA
PHOSPHORYLATED CAV2.2 EXPRESSED IN XENOPUS LAEVIS OOCYTES
FEBRUARY 2012
ANNA-MARIA F. ALVES
B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor John M. Clark

Pyrethroids are insecticides used since the 1970s. They are favored for their low
mammalian toxicity, improved environmental stability and insecticidal potency. Voltagegated sodium channels (VGSCs) are a known target but in vitro evidence indicates that
voltage-gated calcium channels (VGCCs) are also targets. Site-directed mutagenesis of
CaV2.2 (N-type), altering threonine 422 to glutamate (T422E), produces a mutant channel
that acts as if permanently phosphorylated. Deltamethrin increases peak current of T422E
CaV2.2 compared to its antagonistic action on wild type CaV2.2 when expressed in
Xenopus oocytes. Phosphorylation of wild type CaV2.2 is evoked by the phorbol ester
PMA by activating endogenous protein kinase C (PKC) in oocytes. Under steady-state
conditions, deltamethrin increases transient peak current and slows deactivation kinetics
of the PKC phosphorylated channel thereby increasing Ca2+ influx and neurotransmitter
release. Conversely, deltamethrin treatment resulted in no effect on the deactivation
kinetics of the unphosphorylated or T422E channels. Under voltage-dependent
conditions, deltamethrin enhances peak current, and causes a hyperpolarizing shift in
vi

activation midpoint potential of the PKC phosphorylated channel which is consistent with
enhanced Ca2+ influx. The hyperpolarizing shift of activation midpoint potential was not
observed when deltamethrin was applied to the T422E mutant channels indicating that
the other phosphorylation sites on CaV2.2 may be playing a role in the differential effects
observed in the action of deltamethrin on the unphosphorylated channel, the T422E
mutant and the PMA-activated PKC phosphorylation channel.
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CHAPTER 1

INTRODUCTION

1.1 Pyrethroid Insecticides

Pyrethroids are a class of synthetic insecticides used widely since the 1970s both
in agriculture and urban environments. They are derived from the naturally-occurring
insecticide pyrethrum, which is isolated from the flower heads of the chrysanthemum
flower Chrysanthemum cinerariaefolium. Pyrethrum is highly labile due to its instability
in sunlight and water caused by spontaneous cleavage of the central ester bond by
photolysis and hydrolysis, respectively (Soderlund et al., 2002; Hossain et al., 2004). It is
a mixture of six pyrethrin esters: pyrethrin I (Fig. 1) and II, cinerin I and II, and jasmolin
I and II. Pyrethroids (synthetic pyrethrins) were developed to meet the need for potent
insecticides with low mammalian toxicity but without the drawbacks of environmental
instability, which limited the effectiveness of pyrethrum in crop protection and vector
control (Soderlund et al., 2002). Among the pyrethroids, there is no specific substructure,
reactive entity, or molecular moiety that can be identified as the common toxophore
conferring pyrethroid-like insecticidal activity. Instead, toxicity results from the goodness
of fit of the entire molecule at its site of action (Soderlund et al., 2002).
Pyrethroids target the voltage-gated sodium channels (VGSC) of insect pests as
well as those of mammals, although mammalian VGSC vary in their biophysical and
pharmacological properties from the insect channel. These differences result in different
sensitivities of the various mammalian VGSC to pyrethroids (Soderlund et al., 2002). To
date, the binding site of pyrethroids to VGSCs has yet to be elucidated.
1

The voltage-gated calcium channels (VGCC) and voltage-gated chloride channels
(VGClC) are also pyrethroid targets and almost assuredly contribute to the overall
neurotoxicity of the pyrethroids (Soderlund et al., 2002). A subset of α-cyano containing
pyrethroids increased neurotransmitter release in the mammalian brain under
depolarizing conditions. This effect is blocked by -conotoxin GVIA, a specific blocker
of N-type VGCC, thereby implicating this subset of VGCC. The exact binding site on
these channels has likewise yet to be elucidated (Brooks and Clark, 1987; Clark and
Brooks, 1989; Soderlund and Lee, 2001; Hossain et al., 2004; Shafer and Meyer, 2004).

Figure 1.
Figure
1. The chemical structure of pyrethrin I, the most toxic ester of
pyrethrum. This structure is the basis for all pyrethroids (reproduced
from Soderlund et al., 2002) (Soderlund et al., 2002).

1.2 Tremor (T-) and Choreoathetosis with Salivation (CS-) Syndromes
Based on their structure and generally on their ability to produce either a tremor
(T) or a choreoathetosis with salivation (CS) intoxication syndrome, pyrethroids have
been classified into two groups (Soderlund et al., 2002). For the most part, Type I (non α-
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cyano) pyrethroids elicit the T-syndrome and Type II (α-cyano) pyrethroids cause the CSsyndrome of intoxication in mammals. T-syndrome symptoms include hypersensitivity,
stimulus-induced bouts of general tremors, convulsive twitching, coma and death. CSsyndrome symptoms include salivation, jerking leg movements, progressive writhing
convulsions and death (Soderlund et al., 2002). Using a functional observational battery
(FOB), bifenthrin, tefluthrin, β-cyfluthrin and λ-cyhalothrin, which had been previously
uncategorized, were placed within the T/CS-syndrome system (Choi and Soderlund,
2006; Weiner et al., 2009). Based on FOB data, two functional groups were proposed.
Group 1 (T-syndrome) includes pyrethrins, resmethrin, permethrin, S-bioallethrin,
bifenthrin, and tefluthrin. Group 2 (CS-syndrome) includes cypermethrin, deltamethrin,
esfenvalerate, β-cyfluthrin and λ-cyhalothrin (Weiner et al., 2009). By exhibiting features
of both groups, fenpropathrin, an α-cyano pyrethroid which had been previously
described as causing a mixture of T- and CS-syndrome symptomologies and therefore not
definitely a member of either class, remains unclassified (Breckenridge et al., 2009;
Weiner et al., 2009).

1.3 Pyrethroid Neurotoxicity
The differences between how T- and CS-syndrome pyrethroids cause mammalian
neurotoxicity apparently lay in their three-dimensional chemistry. The absence (Type I)
or presence (Type II) of an α-cyano group in the 3-phenoxybenzyl alcohol moiety
provides one of the key differences between the two types of pyrethroid structures. The
presence of the α-cyano moiety provides Type II pyrethroids with a much greater level of
insecticidal potency than their non α-cyano Type I counterparts, while maintaining the
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same level of photostability (Soderlund et al., 2002). Type II pyrethroids are also less
sensitive to ester bond hydrolysis (Brooks and Clark, 1987; Hossain et al., 2004).
Previous studies have shown that Type I pyrethroids that produce the T-syndrome
and Type II pyrethroids that cause the CS-syndrome cause differential effects on the
release of acetylcholine (ACh) from both whole brain and cerebellum of rats (Aldridge et
al., 1978). The study compared the effects of cismethrin (a Type I pyrethroid that causes
T-syndrome) with those of deltamethrin (a Type II that causes CS-syndrome) and found
that only deltamethrin caused significantly more ACh release compared to cismethrin. In
another study, freely moving rats were dosed with allethrin (a Type I pyrethroid that
causes T-syndrome) and deltamethrin and λ-cyhalothrin (Type II pyrethroids that cause
CS-syndrome) (Hossain et al., 2004). In this study, allethrin had a dose-dependent effect
on ACh efflux. Low doses caused an increase in ACh efflux whereas high doses caused a
decrease. Deltamethrin and λ-cyhalothrin had opposite results from one another:
deltamethrin caused a dose-dependent increase in ACh release and λ-cyhalothrin caused a
dose-dependent decrease. The differences apparent in the amount of neurotransmitter
release in the presence of allethrin versus deltamethrin support the contention that some
Type I and Type II pyrethroids may have different sites of action. The differences
between the actions of λ-cyhalothrin and deltamethrin on ACh release despite both being
Type II pyrethroids may, in part, be due to the differences in their three-dimensional
configurations. β-cyfluthrin and λ-cyhalothrin, both close structural analogs of
deltamethrin, prolongs Na+ channel activation and deactivation kinetics beyond that of
deltamethrin (Choi and Soderlund, 2006). Together with the FOB data, the prolongation
of channel kinetics by β-cyfluthrin and λ-cyhalothrin, places the two pyrethroids within
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the CS-syndrome class (Weiner et al., 2009).
The aquatic ciliate Paramecium tetraurelia has been shown to be one of the most
sensitive organisms to pyrethroids, especially deltamethrin (Clark et al., 1995), despite
their lack of VGSCs, long considered a major pyrethroid target (Symington et al., 1999b).
Electrophysiological experiments showed that deltamethrin was toxic to P. tetraurelia
under depolarizing conditions because they caused a significant increase in Ca2+ influx
via their voltage-gated calcium channel, which control cilia motor function. When
exposed to Type-II pyrethroids, P. tetraurelia exhibit increased backwards swimming
behavior, which is controlled explicitly by increased Ca2+ influx via VGCCs (Symington
et al., 1999a; Symington et al., 1999b). Pawn mutants, which lack VGCCs, were
unaffected by deltamethrin and wild type cells were unaffected by the inactive 1S
enantiomer of deltamethrin. Lastly, deciliated paramecia are no longer sensitive to the
toxic action of deltamethrin. In summary, these biochemical and behavioral studies have
shown that: 1) there is a difference in the action of pyrethroids based on the presence or
absence of an α-cyano group, and 2) in addition to VGSCs, VGCCs are also pyrethroid
targets.

1.4 Structure-Activity Relationships
The structure-activity relationship (SAR) for pyrethroids is based on the physical
properties and three-dimensional configuration of the entire molecule. Thus, the activity
of a pyrethroid is based upon how well the entire molecule fits at the site of action and
there exists a wide range of structures that satisfy this requirement (Elliott et al., 1974;
Soderlund et al., 2002).
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The stereospecificity at the C1 carbon of the cyclopropane ring of the acid moiety
is a major SAR that confers insecticidal action. Pyrethroids that have the R configuration
at C1 (1R) have high insecticidal activity whereas pyrethroids in the S configuration (1S)
have no insecticidal activity despite being chemically identical to the 1R enantiomer
(Elliott et al., 1974). For fenvalerate, which does not have a cyclopropane in its acid
moiety, a S configuration around the C2 carbon of the 3-methyl butyrate moiety, which
mimics the 1R configuration of cyclopropane-containing pyrethroids, confers insecticidal
activity whereas the R configuration is not insecticidal (Soderlund et al., 2002).

1.5 Voltage-gated Ion Channels
Members of the voltage-gated ion channel family include sodium (Na+),
potassium (K+), chloride (Cl-) and calcium (Ca2+) ion channels and are found in various
tissues (e.g., skeletal muscle, pancreas, cochlea, kidney, liver and nerve) where they
provide a number of regulatory functions. VGSCs and VGCCs share substantial
structural homology between their pore-forming α-subunits (Catterall, 1997; Shafer and
Meyer, 2004). When either channel is activated, there is an influx of extracellular cations
via the “opened” channel, which is positioned in the plasma membrane, thereby
depolarizing the membrane. The voltage-gated potassium channel (VGPC) assist in
rectifying membrane potential after depolarization by transporting K+ ions out of the cell
to counteract the increase of positive charge on the inside due to the influx of cations
(Na+, Ca2+) through VGSCs and VGCCs (Martinez-Pinna et al., 2000). Ca2+-activated Clchannels also assist in rectifying membrane potential by transporting Cl- ions into the cell
in response to the increase in intracellular Ca2+ (Hartzell et al., 2005).

6

1.6 Structure and Function of VGSCs
VGSCs play a central role in the initiation and propagation of action and
generator potentials of electrically excitable cells, such as neurons (Yu and Catterall,
2003). VGSCs are multimeric proteins made up of an ion conducting pore (α-subunit)
and the two auxiliary β-subunits, β1 and β2. VGSC α-subunits contain four internally
homologous domains, each made up of six α-helical transmembrane segments. β subunits
are membrane-bound subunits connected to α-subunits by disulfide bonds.. Coexpression of β subunits with the α subunit increases the level of functional expression,
causes a shift in the voltage-dependence of activation, and greatly accelerates channel
inactivation (Isom et al., 1992; Isom et al., 1995).
Voltage dependence of the VGSCs plays a central role in the initiation and
propagation of action potentials in nerve axons and in the production of electrical
impulses in other electrically excitable cells. There are three functional characteristics
that are used to identify VGSCs electrophysiologically. The first functional characteristic
of VGSCs is activation which occurs via the outward movement of the positive “gating”
charges on the helical S4 transmembrane segment of each transmembrane domain in
response to changes in the membrane electric field (going from positive to negative on
the outside surface of the membrane during depolarization) (Hodgkin and Huxley, 1952;
Armstrong, 1981; Catterall, 2000a; Catterall, 2000b). The VGSC S4 transmembrane
segment contains a cylindrical α-helix of repeating motifs consisting of one positive
followed by two negative amino acids. When the ion-conducting pore of the channel is
closed, the negatively charged internal electric field of the channel pulls the positively
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charged amino acids of the S4 helix into the cell. In response to depolarization of the
membrane, the S4 segment moves outward from the cell changing the conformation of
the channel from a closed state to an open state thus allowing for the movement of ions
through the ion conducting pore (Catterall, 2000b). The influx of Na+ ions through the
pore formed by the activated α-subunit further depolarizes the membrane and initiates the
rising phase of the action potential. The conformational change of VGSC from a closed to
an open state (activation) as the result of the S4 segments response to membrane
depolarization occurs within a few milliseconds. The influx of Na+ ions through the open
channel into the cell is characterized by a measured transient peak current.
The second functional attribute is channel inactivation, which occurs under
steady-state depolarization in response to channel activation, is characterized by the
decay of “transient peak current”. Under steady-state depolarization, VGSC inactivates
when the inactivation gate, the intracellular III-IV transmembrane loop of the α-subunit,
moves to block the ion-conducting pore by binding to a receptor on the intracellular
mouth of the pore (Armstrong, 1981; Kellenberger et al., 1996; Catterall, 2000b; Kass,
2004). In sodium channels, inactivation is biphasic with the initial phase ηfast and the
slower secondary phase ηslow and is measured as “late current” (Tan and Soderlund,
2009). Fast inactivation (ηfast) is regulated by the inactivation gate and is coupled to
channel activation whereas slow inactivation (ηslow) is voltage-dependent (Kass, 2004).
The third functional attribute is deactivation. The current that occurs after the
removal of steady state membrane depolarization (repolarization) is termed “tail current”
and is a measure of deactivation.
In mammals, multiple VGSC isoforms exist that are encoded by a family of
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homologous genes. Each isoform varies in its sensitivity to pyrethroids, both within and
between the α- and non-cyano structural classes, which make the characterization of
mammalian VGSCs complicated (Goldin et al., 2000; Soderlund et al., 2002; Yu and
Catterall, 2003). The complete VGSC sequences for mammalian isoforms are designated
as NaV1.1-NaV1.9 and each has been functionally characterized as encoding a voltagegated ion channel (Goldin et al., 2000). The expression patterns of the different VGSC
isoforms are tissue dependent and developmentally regulated (Choi and Soderlund,
2006). VGSCs are expressed in cardiac muscles, skeletal muscles and different
anatomical regions of the central and peripheral nervous systems (Yu and Catterall, 2003)
and exist in several states of alertness: closed resting state, open activated state, inactive
open state, and inactive closed state (Rossie, 1999).

1.7 Neuropharmacology of Mammalian VGSC
VGSCs located in the rat dorsal root ganglion neurons can be formally divided
into three groups. VGSCs whose currents are blocked by the neurotoxin tetrodotoxin
(TTX) are TTX-sensitive (TTX-S), VGSCs whose currents are not blocked by TTX
(TTX-resistant; TTX-R) and VGSCs whose currents are partially sensitive to TTX (TTXpartially sensitive; TTX-PS) (Roy and Narahashi, 1992; Ginsburg and Narahashi, 1993;
Ogata and Tatebayashi, 1993; Choi and Soderlund, 2006). Analysis of VGSC isoforms
determined that carriers of TTX-R currents are very sensitive to pyrethroids and had
much faster activation and inactivation rates than VGSC carriers of TTX-S currents
(Ginsburg and Narahashi, 1993; Ogata and Tatebayashi, 1993). NaV1.8, the principle
carrier of TTX-R current is located in the small diameter of the rat dorsal root ganglion
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neuron (DRG), which is part of the peripheral nervous system (Akopian et al., 1996).

1.8 Pyrethroid Neurotoxicity to Mammalian VGSCs
Pyrethroids alter the normal function of VGSC by acting as channel agonists.
Type I pyrethroids (e.g. allethrin, permethrin, tefluthrin, bifenthrin and cismethrin) have
been shown to slow activation and inactivation kinetics of VGSC moderately while
deactivation kinetics (tail current) decayed rapidly. On the other hand, Type II pyrethroids
(e.g., deltamethrin, cypermethrin) slow activation and inactivation kinetics more than
Type I pyrethroids and significantly slow deactivation, leading to extensive prolongation
in the Na+ tail current. Fenvalerate and fenpropathrin, both α-cyano pyrethroids, changed
VGSC kinetics to a degree that was intermediate between the Type I and Type II
pyrethroids. Although fenvalerate has been classified as a Type II pyrethroid based on
other criteria and fenpropathrin has been characterized as a Type II pyrethroid structurally
but is intermediate in its action in a FOB study (Weiner et al., 2009). Fenvalerate and
fenpropathrin slow activation and inactivation kinetics much like Type II pyrethroids, but
tail currents rapidly decay like Type I pyrethroids. Cyhalothrin and cyfluthrin (α-cyano)
also cause extremely slow deactivation kinetics allowing pronounced tail current. In fact,
cyhalothrin effect was greater than that of deltamethrin, which makes it an extreme
example of a Type II pyrethroid that produces the CS-syndrome. The effect of cyfluthrin
on tail current was also greater than deltamethrin, but was not as significant as that of
cyhalothrin (Choi and Soderlund, 2006).
VGSCs mediate the transient Na+ permeability of the cell membrane that is
associated with the production of rising phase of the action potential in vertebrate and
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invertebrate nerves and in vertebrate skeletal and cardiac muscles. Type I pyrethroids
increase the rate of VGSC activation by causing a hyperpolarizing shift of the membrane
potential at which VGSC activate (Shafer et al., 2005), moderately slow channel
inactivation and cause rapidly decaying deactivation kinetics (Choi and Soderlund, 2006).
These effects on VGSC kinetics by Type I pyrethroids produce transient depolarizing
after potentials and result in repetitive firing of action potentials (repetitive discharges),
which are the cause of the T-syndrome (Shafer et al., 2005; Choi and Soderlund, 2006;
Ray and Fry, 2006). Type II pyrethroids in general slow the rate of channel activation and
inactivation but result in persistent tail currents. This prolonged opening of the channel
allows excess Na+ ions to enter the nerve resulting in rapid and substantial membrane
depolarization to the point that the generation of action potentials is no longer possible, a
condition called conduction block (Soderlund and Bloomquist, 1989; Soderlund et al.,
2002; Hildebrand et al., 2004; Shafer and Meyer, 2004; Ray and Fry, 2006).

1.9 Classification and Function of VGCCs
VGSCs are not the only channels affected by pyrethroids. VGCCs, which play a
role in nerve cell excitability, calcium homeostasis, synaptic signaling and gene
expression modulation, are also affected. VGCC are heteromeric protein complexes
made up of α1, β, α2δ, and sometimes λ subunits. There are as many as ten α1 subunit
isoforms of VGCCs (Catterall et al., 2003). Each forms the ion conducting pore of the
channel and contains major determinants for functional and pharmacological properties
of VGCCs. All α1 subunits have four repeating domains, each consisting of six
transmembrane α helical segments (S). There is a membrane associated loop between S5
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and S6 in each domain. The S4 segment of each homologous domain serves as the
voltage sensor for activation (Catterall, 2000a). There are four the β subunit isoforms and
unlike the α1-subunit, all are entirely cytoplasmic. The β subunit modulates functional
characteristics and membrane expression of the α- subunits (Hanlon and Wallace, 2002;
Shafer and Meyer, 2004).
There are five types of VGCC that exist and they are classified based upon their
biophysical, electrophysiological and pharmacological properties (Table 1). VGCC
channel types are functionally characterized into two groups: those that activate under
large depolarizations (high voltage activated; HVA) and those that activate under small
depolarizations (low voltage activated; LVA). HVA channels are further divided based on
the basis of tissue distribution, biophysical and pharmacological properties into two
different gene families; CaV1.2 (L-Type), CaV2.1 (P/Q-type), CaV2.2 (N-Type), and
CaV2.3 (R- type) channels. CaV3.1 (T-type) channels are the only form of LVA channels.
The Cav2 channels are responsible for the release of neurotransmitters in the neocortex,
hippocampus, cerebellum, neuromuscular junction and the peripheral autonomic effectors
(Soderlund et al., 2002; Catterall et al., 2003).Cav1 channels, under certain conditions or
at certain synapses, will also mediate neurotransmitter release (Xu et al., 1998). VGCC
expression is developmentally regulated. Cav2 channels express early during the
development of the nervous system and are most critical in cerebellar granule migration,
gene activation and neurotransmitter release. CaV2.2 from rat brain is the most important
of the VGCCs in neurotransmitter release and in pain transmission pathways (Drean et
al., 1995; Finkbeiner and Greenberg, 1998; Vance et al., 1998; Shafer and Meyer, 2004).
VGCCs are further defined based on the pharmacological profile and functional
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characteristics of each of their α1 subunits. The CaV1 subfamily conducts L-type currents
of the 1S, C, D and F α1 subunits. The CaV2 family conducts N (α1B), P/Q (α1A) and Rtype (α1E) Ca2+ currents. T-type calcium currents are conducted by the CaV3 family of α
subunits (α1G, α1H and α11) (Perez-Reyes, 2003; Shafer and Meyer, 2004). Of these, the
focus of our investigation will be on the CaV2.2, or N-type channel, which is localized at
low density dendrites and high density nerve terminals of many classes of central
neurons, and is the most important VGCC regulating Ca2+ dependent neurotransmitter
release following depolarization of presynaptic nerve terminals (Catterall, 1997).

1.10 Effects of Pyrethroids on VGCCs
In general, pyrethroids decreased transient peak current of VGSC, prolonged
channel inactivation under depolarizing conditions, and slow VGSC closure after
repolarization (deactivation) (Narahashi, 1992). To assess what effect pyrethroids have on
mammals, freely moving rats were dosed with cismethrin (Type I pyrethroid that
produces the T-syndrome) and deltamethrin (Type II pyrethroid that produces the CSsyndrome) (Aldridge et al., 1978). Analysis of neurotransmitter content of the
hippocampus and the whole brain after dosing revealed that deltamethrin significantly
decreased the amount of ACh in each brain region whereas cismethrin did not. Rats
similarly treated with DDT in the same study had no significant increase of ACh release
from either of the brain regions studied compared to the control (Aldridge et al., 1978).
Deltamethrin administered to freely moving rats caused a dose-dependent increase in the
release of ACh from the hippocampus (Hossain et al., 2004).
Together, these studies showed that the CS-syndrome displayed with the dosing of
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most Type II pyrethroids is likely due to target sites other than VGSCs. A hyperpolarizing
shift in membrane potential of VGSCs due to the presence of Type I pyrethroids and
DDT slow channel inactivation and increase late current causing depolarizing after
potentials (DAP). DAP cause spontaneous firing of action potentials and long trains of
repetitive discharges which are related to the tremors produced by T-type pyrethroids.
Type II pyrethroids cause use-dependent conduction block of the action potential and a
depolarizing shift in the resting membrane potential by prolonging deactivation kinetics
and increasing tail currents (Narahashi and Yamasaki, 1960; Soderlund and Bloomquist,
1989; Narahashi, 1992).
The studies in which rats are dosed with Type II pyrethroids, such as deltamethrin,
showed that there was significant neurotransmitter release, a process which is not
controlled by VGSCs, and furthermore these studies showed that Type II poisoning
caused CS-syndrome. These studies also showed that Type I pyrethroids, like DDT,
caused tremors and other symptoms classified under T-syndrome poisoning. It follows
from these studies, therefore, that there are alternative targets for Type II pyrethroids, in
particular VGCCs which do control neurotransmitter release. Comparatively, decreased
peak current and prolongation of activation and inactivation kinetics were observed in
deltamethrin-treated N-type VGCC (CaV2.2), but deactivation kinetics remained
unmodified (Symington and Clark, 2005). In rabbit striatal slices, cypermethrin,
deltamethrin, and fenvalerate evoked neurotransmitter release 3- to 5-fold above the
spontaneous release. Furthermore, fenvalerate also elicited a stereospecific and
concentration-dependent release of neurotransmitters from the rabbit striatal slices (Eells
and Dubocovich, 1988). In mouse spermatogenic cells, fenvalerate reduced T-type Ca2+

14

current and caused a hyperpolarizing shift in the current-voltage relationship of the
channel as well as the steady-state inactivation of the channel (Xiao et al., 2006).
Pyrethroids also block distinct classes of VGCCs in a variety of non-neuronal
mammalian systems. Two distinct VGCC types from mouse neuroblastoma cells (N1E115), a transient (T-type) and a long lasting (L-type) Ca2+ current, were examined
(Narahashi et al., 1987). Tetramethrin, a T-syndrome pyrethroid, preferentially blocked Ttype calcium current by 75% but only 30% of the L-type current (Yoshii, 1985). More
recent electrophysiological studies using CaV3.1 (T-type), CaV1.2 (L-type), and CaV2.1
(P/Q-type) expressed in non-neuronal HEK cells indicated that all three current types
were effectively blocked by allethrin (a Type I, T-syndrome-producing pyrethroid). The
block caused an increase in the rate of channel inactivation during steady-state
depolarization as well as a hyperpolarizing shift in the voltage-dependent inactivation
(Hildebrand et al., 2004). The contributions of these effects are consistent with the
channel block observed.
The increase in the rate of inactivation and the insignificant change in tail current
of CaV3.1, CaV1.2 and CaV2.1 in the presence of allethrin is inconsistent with earlier
studies that have shown pyrethroids to delay inactivation and slow the deactivation of tail
currents (Vais et al., 2000; Soderlund et al., 2002; Wang and Wang, 2003; Hildebrand et
al., 2004)
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Table 1. Voltage-gated calcium channel (VGCC) subunit compositions and functions
(adapted from Catterall 2003 (Catterall et al., 2003)).
Ca2+ Current
Primary
Ca2+ Channels
Cellular Functions
type
Localizations
CaV1.1
L
Skeletal muscle
Excitation-contraction
coupling
Calcium homeostasis
Gene regulation
CaV1.2
L
Cardiac muscle
Excitation-contraction
Endocrine cells
coupling
Neurons
Hormone secretion
Gene regulation
CaV1.3
L
Endocrine cells
Hormone secretion
Neurons
Gene regulation
CaV1.4
L
Retina
Tonic neurotransmitter
release
CaV2.1
P/Q
Nerve terminals
Neurotransmitter release
Dendrites
Dendritic Ca2+ transients
CaV2.2
N
Nerve terminals
Neurotransmitter release
Dendrites
Dendritic Ca2+ transients
CaV2.3
R
Cell bodies
Ca2+ -dependent action
Dendrites
potentials
Nerve terminals
Neurotransmitter release
Repetitive firing
CaV3.1
T
Cardiac muscle
Repetitive firing
Skeletal muscle
Neurons
CaV3.2
T
Cardiac muscle
Repetitive firing
Neurons
CaV3.3
T
Neurons
Repetitive firing
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al., 2004). Comparatively, deltamethrin has been shown to partially block CaV2.2 (Ntype) currents heterologously expressed in Xenopus oocytes, which was accompanied by
a slight hyperpolarizing shift in the voltage dependence of activation and a slowing of
channel activation and inactivation (Symington and Clark, 2005). Peak, end, and tail
currents of L-type (CaV1) Ca2+ channels expressed in PC12 cells significantly increased
in the presence of allethrin and voltage-dependent peak current was shifted to more
hyperpolarizing potentials(Neal et al., 2010). Neal et al (2010) also showed allethrin
caused a shift in voltage-dependent activation and inactivation kinetics. The differential
effects of allethrin on VGCCs indicate that Type I pyrethroids target some VGCC
subtypes, but not others, in addition to targeting VGSCs. The differential effects may be
due to the phosphorylation states of the channels or other forms of post-translational
modifications. Type II pyrethroids certainly have an effect on VGCCs but again, the
degree to which they have an effect appears to be based on the post-translational
modification state of the channel.

1.11 Role of CaV2.2 in Neurotransmitter Release
CaV2.2 is expressed in presynaptic nerve terminals and is the predominant
channel that regulates calcium-dependent, vesicle-mediated neurotransmitter release
during membrane depolarization. The treatment of isolated presynaptic nerve terminals
(synaptosomes) with deltamethrin causes an increase in neurotransmitter release as a
result of Ca2+ influx via CaV2.2 (Augustine et al., 1987). Treatment of deltamethrin, a
Type II/CS-syndrome pyrethroid, on CaV2.2 expressed in Xenopus oocytes resulted in a
hyperpolarizing shift of the midpoint potential of activation, prolonged inactivation, and

17

decreased peak current. These effects were stereospecific and dose-dependent
(Symington and Clark, 2005). Enhanced activation and prolonged inactivation kinetics of
heterologously expressed CaV2.2 is consistent with increased neurotransmitter release
observed from the treatment of synaptosomes with deltamethrin. However, the inhibition
of peak current may be inconsistent with the enhanced neurotransmitter released
observed in treated synaptosomes (Symington and Clark, 2005).
CaV2.2 exists either in a “willing” or a “reluctant” state. In the willing state, the
channel undergoes rapid activation during depolarization to voltages within its
physiological range. In the reluctant state, the channel undergoes slow activation at more
positive voltages beyond its normal range of physiological membrane potential (Catterall,
2000a). Channel conductance is regulated by two separate processes: activation and
inactivation. Activation controls the time and voltage dependence required to open the
channel after depolarization and inactivation measures the voltage and time dependence
of channel closure during maintained depolarization (Catterall, 1997; Hanlon and
Wallace, 2002). Deactivation is a third kinetic measurement that describes the time
dependence of complete closure of channels that have activated but not inactivated after
the removal of membrane depolarization (Kostyuk and Shirokov, 1989).
Activation and inactivation kinetics can be modified by several proteins and
through phosphorylation of the α-subunit by protein kinases. The Gβγ subunit of the
heteromeric G-proteins and SNARE proteins can modify channel kinetics by direct
binding to the transmembrane domains of the α1 subunit. Modulation by Gβγ causes a
hyperpolarizing shift in voltage dependence and slows channel activation.
Phosphorylation of the α1D channel at T422 or S425 (Fang et al., 2006) downstream of
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where Gβγ interacts on the I-II intracellular loop or a strong depolarization can reverse the
Gβγ inhibitory effect, resulting in increase Ca2+ currents. Unlike Gβγ, channel regulation
by SNARE is Ca2+ dependent. Regulated by Ca2+, presynaptic CaV2.2 interacts directly
with SNARE proteins and synaptotgamin. The interaction of SNARE proteins and
CaV2.2 is required to dock synaptic vesicles near Ca2+ channels for fast and effective
exocytosis and the interaction is considered crucial for synaptic transmission (Catterall,
2000a). Locations on the synaptolemma where these processes co-organize are called
“active release zones”. When both Gβγ and SNARE proteins become phosphorylated,
they no longer have an effect on the channel. All members of the CaV2 subfamily are
blocked by ω-conotoxin GVIA but CaV2.2 has the highest affinity for this channel
blocker. Inhibition of CaV2.2 by ω-conotoxin GVIA causes a hyperpolarizing shift in
voltage dependence and a slowing of channel activation, which can be alleviated by a
strong depolarization resulting in Ca2+ current facilitation (Catterall, 2000a).

1.12 Differences between in vivo and in vitro Action of Deltamethrin on CaV2.2
Assays involving isolated presynaptic nerve terminals (synaptosomes) treated
with deltamethrin were analyzed for enhanced Ca2+ influx and neurotransmitter release.
Deltamethrin caused a significant increase in Ca2+ influx and glutamate release from
synaptosomes in a concentration-dependant and stereospecific manner. No decrease in
Ca2+ influx was observed when synaptosomes pretreated with the VGSC blocker
tetrodotoxin (TTX), showing that Ca2+ influx was not VGSC-dependent and that there are
additional sites at which deltamethrin is acting (Symington and Clark, 2005). The
increase in Ca2+ influx that was the result of deltamethrin treatment and the deltamethrin-
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enhanced release of glutamate were abolished when synaptosomes were pretreated with
the N- and P/Q- type Ca2+ channel blocker ω-conotoxin MVIIC (Symington and Clark,
2005).
The N-type VGCC isolated from rat brain (CaV2.2) were heterologously
expressed in Xenopus oocytes, a non-neuronal expression system, to determine the
specific effects of deltamethrin on this channel. Deltamethrin stereospecifically reduced
the Ba2+ peak current in a concentration dependent manner. Treatment of CaV2.2 with
deltamethrin caused a hyperpolarizing shift in the voltage-dependent activation kinetics
of the channel as well as prolonging inactivation gating characteristics. The
hyperpolarizing shift in the voltage-dependent activation of CaV2.2 as well as the
prolongation of the inactivation kinetics means that the channel is more sensitive to
opening at lower potentials and stays open longer allowing for more Ba2+ ions to influx
through the channel (Symington and Clark, 2005).

1.13 Protein kinase C (PKC)
Phosphorylation also plays an important role in the modulation of CaV2.2.
Phosphorylation of CaV2.2 can reverse Gβγ inhibition and cause an up regulation of Ca2+
currents via CaV2.2 expressed in intact neurons and transient expression systems. Protein
kinase C (PKC) is responsible for the phosphorylation of CaV2.2 and the subsequent
antagonism of G protein-mediated inhibition of the channel. This interaction between
PKC and Gβγ is termed “cross talk” (Swartz, 1993; Zamponi et al., 1997; Cooper et al.,
2000; Doering et al., 2004).
PKC takes part in cellular responses to various agonists including hormones,
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neurotransmitters and some growth factors. Agonist-induced hydrolysis of inositol
phospholipids by phospholipase C produces IP3, which releases Ca2+ stores from
endoplasmic reticulum. Cytosolic free Ca2+ and membrane-bound diacylglycerol (DAG)
react to activate PKC. Metabolically-stable, tumor-promoting phorbol esters, such as
phorbol ester 12-myristrate, 13-acetate (PMA), mimic DAG activity in a Ca2+
independent manner and are capable of activating PKC for longer periods of time than
DAG and several doses of DAG are required to achieve the same effect as one dose of a
phorbol ester (Nishizuka, 1992; Mosior and Newton, 1996; Newton, 2001).
The protein kinase C (PKC) enzyme family consists of ten Ser/Thr
phosphotransferases and is divided into three subfamilies: conventional (PKCα, PKCβ1,
PKCβ2, PKCγ), novel (PKCδ, PKCζ, PKCε, PKCε) and atypical (PKCδ, PKCλ). Every
PKC has a regulatory domain and a catalytic domain. Within their regulatory domains,
conventional and novel PKCs contain two C1 domains and a C2 domain, both of which
are targets for different second messengers. Atypical PKCs only contain a single C1
domain. Common to all three subfamilies of PKC are domains C3 and C4 which make up
the catalytic domain of PKC. Phosphorylation of PKC occurs at threonine 567 on the
activation loop by phosphoinositide-dependent kinase (PDK-1) quickly followed by
phosphorylation of threonine 711 on the turn motif and serine 729 in the hydrophobic
region by autophosphorylation. Phosphorylation and the binding of cofactors induce long
range conformational changes that regulate the domain interactions.
PKC exists under acute structural and spatial regulation. Its state of
phosphorylation, conformation and sub-cellular location must each be tightly controlled
for PKC to function properly. The catalytic domain comprises a conserved kinase core
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containing the ATP-binding site, consensus phosphorylation sites, substrate binding and
phototransfer sites (Newton, 2001; Corbalán-García and Gómez-Fernández, 2006). In
order for PKC to become catalytically active, phosphorylation has to occur at three sites
in the catalytic domain of the enzyme. Sites on the activation loop (Thr567), turn motif
(Thr711), and hydrophobic motif (Ser729) of the PKC catalytic domain are
phosphorylated via different mechanisms. The cofactors that regulate PKC conformation
are phosphatidylserine (PS), DAG and Ca2+. Not all of the cofactors regulate all of the
PKCs. Conventional PKCs are regulated by PS, DAG and Ca2+. Novel PKCs are
regulated by PS and DAG. Atypical PKCs are regulated by just PS. Despite
phosphorylation of its catalytic domain and its translocation to the membrane via binding
of DAG and PS, PKC can still be held in an inactive state by the occupation of its kinase
core by its pseudosubstrate (Newton, 2001). In order for unimpaired signaling of PKC to
occur, its catalytic domain needs to be phosphorylated, PKC needs to translocate from the
cytosol to the membrane via binding of its C1 and C2 domains to DAG and PS,
respectively, and the allosterically regulating pseudosubstrate needs to be released from
the kinase core.
DAG, a product of phospholipase C (PLC) hydrolysis of phosphatidyl inositolbiphosphate (PIP2), is a second messenger phospholipid that binds to the C1 region of
PKC and in the process of activating the protein, sequesters it to the plasma membrane
(Liu and Heckman, 1998). The effects of phorbol esters on PKC are slightly different
from the effects of DAG although they operate by the same mechanism (Newton, 2001).
Their biological effects differ for two reasons: 1) membrane recruitments and activation
by DAG is short lived because DAG is rapidly metabolized whereas phorbol esters are
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not, and 2), phorbol esters are two times more potent than DAG on a molar basis in
recruiting PKC to membranes.
Several different isozymes of PKC exist in neuronal channels and each has its
own particular set of substrates. It has been shown that novel PKC, PKCε, is specific to
phosphorylating CaV2.2 through the adaptor protein enigma homolog (ENH) (Newton,
2001; Maeno-Hikichi et al., 2003), but in many cases, the presence of ENH is not
required to phosphorylate the Ca2+ channel (Stea et al., 1995; García-Ferreiro et al., 2001;
Maeno-Hikichi et al., 2003). PKCε has also been confirmed to be present in Xenopus
oocytes although it remains inactive unless activated by PMA (Maeno-Hikichi et al.,
2003).

1.14 Dephosphorylation by Protein Phosphatases
Multiple families of Ser/Thr protein phosphatases (PP) have been identified in the
brain and include PP1, PP2a, PP2b and PP2c. Just as individual kinases are capable of
mediating unique cellular functions by adding phosphate groups to proteins, PPs are
capable of removing phosphate groups from CaV2.2. However, much less is understood
about which PP is responsible in regulating neuronal Ca2+ channel activity (Li et al.,
2005).
It is yet to be determined which PP removes the phosphate group from T422 on
CaV2.2. Of the five possible phosphorylation sites on the I-II and II-III intracellular loops
of CaV2.2 for PKCε to interact with (Maeno-Hikichi et al., 2003; Fang et al., 2006), Li et
al. (Li et al., 2005) have demonstrated that the protein phosphatase PP2cα was more
effective in dephosphorylating the II-III intracellular loop than its PP counterparts. As for
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the I-II intracellular loop, which includes T422, none of the PPs examined by Li et al.
were effective in their individual ability to dephosphorylate the region, but when
combined, the dephosphorylation rate of the I-II loop increased.

1.15 Effect of PMA-activated PKC modulation on Wild Type CaV2.2
PKC is a regulatory enzyme that phosphorylates serine and threonine residues.
PMA up regulates PKC phosphorylation, which results in the addition of phosphate
groups to residues Thr422 (T422), Ser425 (S425), Ser1757 (S1757), Ser2108 (S2108)
and Ser2132 (S2132) (Stea et al., 1995; Fang et al., 2006). Phosphorylation of CaV2.2
removes G-protein mediated inhibition via the Gβγ subunit, which allows increased Ca2+
influx and a subsequent increase in neurotransmitter release (Nichols et al., 1987; GarcíaFerreiro et al., 2001). Stea et al. (Stea et al., 1995) showed that within Xenopus oocytes,
PMA-activated endogenous PKC phosphorylates heterologously expressed CaV2.2,
which elicits a time-dependent increase in peak current. PMA enhancement of PKC
activity in rat brain caused enhanced excitatory synaptic transmission (Swartz et al.,
1993), reduced suppression by metabotropic glutamate receptor (G-protein mediated)
agonists (Barrett and Rittenhouse, 2000), enhanced whole cell current amplitude in
sympathetic neurons (García-Ferreiro et al., 2001) and increased Ca2+-dependent
neurotransmitter release from synaptosomes (Nichols et al., 1987; García-Ferreiro et al.,
2001). Thus, VSCCs are modulated by direct phosphorylation that alter channel
sensitivities to changes in membrane potential or channel ability to undergo
conformational changes from an open state to inactive or closed states (Rossie, 1999).
Treatment of synaptosomes with phorbol esters stimulated endogenous PKC activity,
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which resulted in enhanced Ca2+-dependent neurotransmitter release (Nichols et al.,
1987). These results are consistent with the contention that PKC phosphorylation changes
VSCC sensitivity to membrane depolarization and causes an increase in Ca2+ influx and
neurotransmitter release.

1.16 Mutant CaV2.2
It has been shown that deltamethrin has an agonistic effect on Ca2+ influx and
neurotransmitter release in rat brain synaptosomes (Aldridge et al., 1978; Hossain et al.,
2004; Symington and Clark, 2005; Symington et al., 2007b). However, deltamethrin
inhibits Ba2+ peak current when CaV2.2 is heterologously expressed in Xenopus oocytes
(Symington and Clark, 2005). This difference in channel response to deltamethrin
treatment, depending on the expression system, is believed to be due, in part, to the lack
of active post-translational modifications in the non-neuronal oocytes versus active posttranslational modifying enzymes, such as protein kinases, within rat brain synaptosomes.
The intracellular loop between domains I and II on the CaV2.2 α1 subunit is a
highly regulated domain (the alpha-subunit interacting domain, AID), which contains
T422 and the overlapping binding sites for PKC, Gβγ and the VGCC β subunit (Cooper et
al., 2000). A specific phosphorylation of CaV2.2 by PMA-activated PKC can be
mimicked by an amino acid substitution in the PKC regulatory site within the I-II
intracellular domain. Conversion of threonine 422 to glutamic acid (T422E) results in a
channel that functions as if it were permanently phosphorylated since glutamic acid is
negatively charged at physiological pH. This mutation produces a CaV2.2 phosphoform
that mimics the effect of PMA up-regulation and is no longer sensitive to Gβγ inhibition
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(Hamid et al., 1999; Cooper et al., 2000; Symington et al., 2007a).
Using this approach, it has been shown that the T422E mutation alters the action
of deltamethrin on CaV2.2 expressed in Xenopus oocytes (Symington et al., 2007a).
Deltamethrin significantly enhanced peak current via the T422E channel compared to the
wild type, the solvent-treated control and a T422A (permanently unphosphorylated
mutant) channel. This effect was stereospecific and concentration dependent. Additional
effects of deltamethrin on T422E included a more positive activation midpoint potential,
a depolarizing shift in the voltage dependence of activation. However, no change in the
activation or inactivation tau values was observed as seen previously on the wild type
channel. As demonstrated in the mutant T422E experiments, CaV2.2 is clearly modified
by deltamethrin but the resulting perturbation is highly dependent upon the
phosphorylation state of T422.

1.17 The Effect of PMA-activated PKC Phosphorylation on Wild Type CaV2.2 is
enhanced by Deltamethrin Treatment
Post-translational modifications of CaV2.2 have been suggested to be the cause of
the differences between the agonistic effect deltamethrin elicited in rat brain
synaptosomes versus its antagonistic effect on the Ba2+ peak current via heterologously
expressed CaV2.2 in Xenopus oocytes. The increase in peak current following
deltamethrin treatment of T422E is highly suggestive that the phosphorylation state of
CaV2.2 determines its response to deltamethrin (Symington et al., 2007a).
Using PMA to up regulate PKC activity in Xenopus oocytes, CaV2.2 is readily
phosphorylated, although phosphorylation of the channel is nonspecific (Cooper et al.,
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2000). It is our contention that deltamethrin enhances Ca2+ influx and subsequent
neurotransmitter release only when acting upon a phosphorylated channel. By activating
PKC with PMA, we are able to nonspecifically phosphorylate CaV2.2, which was
heterologously expressed in Xenopus oocytes, and enhance channel conductance. We
expect that the addition of deltamethrin and other CS-syndrome pyrethroids will further
enhance the conductance of phosphorylated CaV2.2 in a stereospecific manner. By
analyzing peak current and channel kinetics, such as activation, inactivation, deactivation,
we will investigate which channel properties are influenced by phosphorylation in the
presence and absence of pyrethroids.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Materials
Technical grade deltamethrin ((S)-α-cyano-3-phenoxybenzyl (1R,3R)-3-(2,2dibromovinyl)-2,2-dimethylcyclopropanecarboxylate; isomeric composition: 95.0% (Z)(1R)-cis-)) was provided by Aventis CropScience (Dublin, NJ), a member of the
Pyrethroid Working Group (PWG); a conglomerate of the major pyrethroid manufactures
in the United States and United Kingdom and includes Valent USA Corp. (Montvale, CA)
and Syngenta (Cheshire, UK), FMC (Philadelphia, PA), DuPont Agricultural Products
(Newark, NJ), and Bayer Corp. (Kansas City, MO). Phorbol 12-myristate, 13-acetate
(PMA; ≥99% pure) was purchased from Calbiochem (# 524400; La Jolla, CA). 4αphorbol 12-myristate, 13-acetate (4α-PMA; 98%) was purchased from Sigma-Aldrich (#
79352; St. Louis, MO). An isomeric mixture of cypermethrin was provided by Shell Corp
(Houston, TX). Pyrethroid, PMA and 4α-PMA stocks were prepared in dimethyl
sulfoxide (DMSO) and diluted with either DMSO or BaCl2 recording solution as
required. Chemical structures for pyrethroids and phorbol esters used in this study are
included in Appendix A.

2.2 Animals
Female Xenopus laevis frogs (7.5-9 cm) were purchased from Nasco (Fort
Atkinson, WI) and maintained on a 12:12 hr day and night light cycle in a 19 oC
incubator. Animals were housed in plastic bins (61.54 cm x 41.45 cm x 32.47 cm) in 5
gallons of dechlorinated water at 5 females per bin. Animal procedures were conducted in
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accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines
(Protocol #: 27-09-06R) entitled “Pharmacological and toxicological effects of pesticides
on ion channels and ABC transporters expressed in Xenopus laevis oocytes” submitted by
J.M. Clark, principle investigator.

2.3 CaV2.2 RNA Preparation
Full length CaV2.2 cDNA α1 and β3 clones were provided as a gift from Dr. Diane
Lipscombe (Brown University, Providence, R.I.). Linearized cDNA was checked by
electrophoresis on a 0.8 % agarose gel against a High Mass DNA Ladder (10496-016;
Invitrogen). cDNA isolation and purification were performed following manufacturer’s
instructions for the QIAquick® Gel Extraction Kit (QIAGEN, Valencia, CA). In vitro
transcription was performed using the mMessage mMachine® High Yield Capped RNA
Transcription Kit (# AM1344; Ambion Inc., Austin TX) (Lin et al., 1997; Symington and
Clark, 2005; Symington et al., 2007a).
Specifically, CaV2.2 α subunit cRNA was prepared for oocyte injection from the
cDNA clone RNα1B-d (vector pBSTA rscg1B-b, 3.19 kb). The β3 auxiliary subunit cRNA
was prepared from the cDNA clone (vector pcDNA3.1zeo+, 5 kb). CaV2.2 and β3 cDNAs
were checked on a 0.8% agarose gel (0.4 g agarose, 50 ml 1X Tris-Acetate EDTA (TAE)
buffer and 1 µl ethidium bromide (10 mg/ml)) run at 100 mV for 1 hr and measured
against a High Mass DNA Ladder.
cDNA isolation and purification was performed using the QIAquick® Gel
Extraction Kit. Three volumes of Buffer QG and 1 volume of isopropanol were added to
the reaction mixture and mixed by repetitive pipetting until homogenous. The entire

29

sample was applied to the supplied spin column and centrifuged for 1 min at 15,690g.
The flowthrough was removed from the catch tube. PE buffer (0.75 ml) was added to the
spin column and after a 1 min equilibration interval the column was recentrifuged as
before. The spin column was transferred to a new centrifuge tube. The concentration of
cDNA was determined by gel electrophoresis on a 0.8% agarose gel stained with
ethidium bromide and measured against a High Mass DNA Ladder prior to isolation and
purification so that an appropriate amount of elution buffer (EB) could be added to ensure
that the cDNA concentration after isolation and purification was equal to 1 μg/μl (20-50
μl). The appropriate amount of EB was added and the spin column was recentrifuged.
The purity of the eluted cDNA was checked by electrophoresis on a 0.8% agarose gel
stained with ethidium bromide at 100 mV for 1 hr and measured against a High Mass
DNA Ladder. The remainder of the cDNA was stored at -20oC until used for in vitro
transcription. cDNA concentration was determined using a ND-1000 UV-Vis
Spectrophotometer (Thermo Fisher Scientific Wilmington, DE). The ND-1000 UV-Vis
Spectrophotometer forms a column of sample (2 μl of purified DNA) between the sample
pedestal and the arm of the spectrophotometer. The pedestal moves to automatically
adjust the length of the sample column for an optimal path length (0.05 mm to 1.0 mm)
for measurement of the optical density (absorbance) of the sample at 260 nm.
Concentration of the sample is calculated using the Beer-Lambert Law (Equation 1):

Equation 1
A = εcl
Where:
A = the absorbance of the sample at 260 nm
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ε = the absorption coefficient of DNA (50)
c = the concentration of the sample
l = the path length
In vitro transcription was performed using the mMessage mMachine® High Yield
Capped RNA Transcription Kit. To the CaV2.2 α1 and β3 reaction mixtures, 1 μl of 30
mM GTP cap, 2 μl of 10X Reaction Buffer, 1 μg of either α1 or β3 CaV2.2 DNA, 10 μl of
2X NTP cap, 2 μl of 2X Enzyme mix and RNase-free ddH2O (diethyl pyrocarbonate
(DEPC)-treated) up to 20 μl were added and mixed. The reaction was incubated at 37oC
for 2 hr, 2 U/μl Turbo DNase was added, and the mixture incubated for an additional 15
min. The reaction was stopped by adding 30 μl nuclease free ddH2O and 30 μl of the
LiCl2 solution provided to precipitate the cRNA. Reaction mixtures were chilled for
approximately 30 min at -20oC before pelleting the cRNA by centrifuging at 4o C for 15
min at 16,170g. After decanting the supernatant, the cRNA pellet was washed with 70%
ethanol and re-centrifuged. Ethanol was removed via pipette and the cRNA resuspended
in 12 µl RNase free ddH2O. cRNA was electrophoressed on a 1% agarose gel (0.5 g
RNase free agarose, 36 ml of 0.01% DEPC-treated ddH2O ) and measured against a RNA
marker (0.2- 10 kb, R-7020; Sigma Aldrich St. Louis, MO). The gel was run at 50 mV for
3-5 hr at 4oC. The running buffer was 450 ml of 0.01% DEPC-treated ddH2O and 50 ml
of 10X MOPS (Swanson and Folander, 1992). cRNA concentration was determined using
a ND-1000 UV-Vis Spectrophotometer (RNA absorption coefficient = 40) as described
above and cRNA was stored at -80oC.

2.4 Xenopus Surgery and Oocyte Preparation
Oocytes were obtained surgically from a female Xenopus laevis frog anesthetized
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in a 3-aminobenzoic acid ethyl ether (tricane) solution (2 g/L). Excised oocyte lobes were
washed with OR2 solution (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM N-(2hydroxyethyl)piperazine-N′-2-ethanesulfonic acid (HEPES), pH 7.5). Most of the oocyte
follicle membranes were digested with equal parts collagenase solution (Sigma Type 1A
collagenase; 0.5 U/ml (2 mg/ml)) and OR2 solution. The remaining follicle membranes
were removed manually using fine forceps under a stereomicroscope. Healthy stage V-VI
oocytes were maintained at 19oC in oocyte supplemental media (ND96 media (96 mM
NaCl, 2 mM KCl, 1.8 mM CaCl2·2H2O, 1 mM MgCl2·6H2O, 5 mM HEPES, pH 7.5)
supplemented 1% sodium pyruvate, 2% antibiotics (penicillin, streptomycin) and 5%
horse serum) (Goldin, 1992).
Surgery was done under semi-sterile conditions following IACUC procedures
outlined in Protocol No. 27-09-06R. A female frog (7.5-9 cm) was placed into a tricane
solution (2 g/L) for 10-15 min. Anesthesia was checked by placing the frog upside down
to see if she could right herself and by lack of foot-pinch reflex. If anesthesia was not
complete, the frog was left in the tricane solution for up to 30 min. The anesthetized frog
was placed on its back on a clean, wet surface. A 1.0 cm incision was made from the
lower medial to lateral abdomen toward the head using a sterile surgical blade cutting
through both the skin and underlying membrane. Ovary lobes were pulled through the
incision with a pair of forceps until a sufficient number of oocytes (about 200-300) were
exposed and removed by cutting the connective follicle membrane with a pair of
dissecting scissors. The remaining ovary lobes were placed back into the frog’s abdomen
and the inner and outer membrane incisions were closed separately using a surgical suture
(4-0 chromic gut, Angiotech, Reading, PA) (Goldin, 1992). Excised oocyte lobes were
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washed three times with 20-30 ml of OR2 solution, placed in a 15 ml conical vial
containing 5 ml collagenase solution (Type 1A collagenase; 0.5 U/ml (2 mg/ml)) and 5
ml OR2 solution, and incubated on an orbital shaker at 35 rpm at room temperature for
15-18 min or until the solution became cloudy. Collagenase/OR2 solution was discarded,
replaced every 7-9 min with fresh solution, and treatment was continued until
approximately half the oocytes were fully defollicated. The remaining follicle membranes
were removed manually using fine forceps under a stereomicroscope. Healthy stage V-VI
oocytes were selected based on uniform pigmentation, size and shape. They were
maintained at 19oC in oocyte supplemental media.

2.5 cRNA Injection
Stage V and VI oocytes were co-injected with 46 nl of a cRNA solution
containing the α1 (stock solution 1 μg/μl) and the β3 (stock solution 0.33 μg/μl) subunits
of CaV2.2 using a nanoliter 2000 injector (World Precision Instruments, Sarasota FL) in
25 nl increments. Injected oocytes were stored in oocyte supplemental media at 19oC
until used in expression experiments (Shih et al., 1998).

2.6 Electrophysiology
The function of wild type CaV2.2 α1B subunit co-expressed with the β3 subunit in
the Xenopus oocytes was assayed using the two-electrode voltage clamp (TEVC)
technique by measuring inward Ba2+ currents. The function of wild type CaV2.2 α1B
subunit co-expressed with the β3 subunit in the Xenopus oocytes was assayed using the
two-electrode voltage clamp (TEVC) technique by measuring inward Ba2+ currents.
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The function of wild type CaV2.2 α1B subunit co-expressed with the β3 subunit in
the Xenopus oocytes was assayed using the TEVC technique. Recordings were made in
siliconized culture well oocyte recording chambers (250 l bath volume; C7485-20EA,
Sigma-Aldrich, St. Louis, MO) containing Ba2+ recording solution (5 mM BaCl2, 85 mM
tetraethylammonium, 5 mM KCl, 5 mM HEPES, adjusted to pH=7.4 with
methanesulfonic acid) using a GeneClamp 500B amplifier (Axon Instruments, Union
City, CA). Voltage and current microelectrodes with resistances between 0.5-3.0 M
were made from borosilicate glass using a Narishige PP-83 electrode puller and filled
with 3 M KCl. The electrodes were coated with silver conductive paint (CW2200STP,
Chemtronics, Kennesaw, GA), over coated with insulating resin (CW3300C,
Chemtronics), and shielded with grounded aluminum foil to minimize noise. Data were
digitized at 20 kHz using the Digidata 1322A digitizer, stored by the pClamp (ver. 9.2,
Axon Instruments, Union City, CA) software, and capacitive transient current subtracted
online using the P4 protocol.
Waveform protocols for the Transient, Activation, Inactivation and Deactivation
Test Protocols are shown in Figure 2. To test for CaV2.2 channel expression, the Transient
Test Protocol was applied to each oocyte by depolarizing the plasma membrane from a
resting potential of -80 mV to 10 mV for 150 ms and returning to resting potential (Fig.
2A). Recordings were made every minute for 10 minutes to judge the time course of the
effects of each of the pyrethroids and PMA on Ba2+ peak current via expressed CaV2.2.
From these recordings, the treatments effects on transient peak current (the most

34

Figure 2. Waveform protocols for Transient, Activation, Inactivation and Deactivation
tests. (A) Transient peak current, activation tau and deactivation tau can be
measured directly from the Transient Test Protocol. (B) V50inact and
Inactivation tau, the rate of closure during depolarization, are best measured
from the Inactivation Test Protocol. V50inact is measured as a function of
increasing levels of long-term (2 s) depolarizations. (C) The Deactivation Test
Protocol measures the rate of channel closure (deactivation tau) as a function of
decreasing levels of repolarization. (D) To best measure activation tau (ms), the
Activation Test Protocol measures the rate of activation as a function of
increasing levels of depolarization. Orange lines indicate a sample sweep from
the Activation, Inactivation and Deactivation Test Protocols.
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negative amplitude of current evoked from the depolarization step; μA), steady-state
activation tau (the rate of channel opening during the depolarization step; ms), steadystate inactivation tau (the rate of channel inactivation during the depolarization step; ms)
and steady state deactivation tau (the rate of channel closing after the removal of the
depolarization step; ms) at 4 min and 10 min post treatment were obtained and used for
statistical analysis.
In the Activation Test Protocol, the membrane potential was step-depolarized in
10 mV increments from a resting potential of -80 mV to a final level of 40 mV. The
duration of each depolarization step is 10 ms before the membrane potential is
repolarized back to -80 mV (Fig. 2B). The Activation Test Protocol was used to
determine the effect our treatments have on CaV2.2 voltage dependent peak current,
voltage-dependent activation taus, and voltage-dependent activation midpoint potentials
(V50act).
The Inactivation Test Protocol has two depolarization phases. The first lasts for 2
s and undergoes step-depolarization by an additional 10 mV per sweep starting at -120
mV and ends with a final step depolarization to 0 mV. Each sweep of the first phase of
the Inactivation Test Protocol is immediately followed by the second phase of the
protocol, which is the depolarization of the membrane from the current level of the first
phase to 0 mV for 50 ms (Figure 2C). Recordings were made at 4 min and 10 min post
application of treatment. Using the Inactivation Test Protocol, we were able to determine
what effects our treatments had on CaV2.2 voltage-dependent inactivation midpoint
potential (V50inact) based on the measurement of late current.
The Deactivation Test Protocol also has two phases: a depolarization phase and a
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repolarization phase. During the depolarization phase of the protocol, the membrane is
depolarized from a resting potential of -80 mV to 0 mV for 10 ms. The repolarization
phase occurs immediately following the depolarization phase. During the repolarization
phase, the membrane is repolarized in decreasing steps by 10 mV starting with the
repolarization step to -80 mV during the first sweep and ending at 0 mV during the last
sweep. Each repolarization level is held for 100 ms and recordings were made at 4 min
and 10 min post treatment (Figure 2D). The Deactivation Test Protocol was designed to
determine what effects our treatments have on voltage-dependent deactivation taus.

2.7 Measuring PMA and Pyrethroid Effects on CaV2.2 Inward Transient Peak
Current
Initially, a Transient Test Protocol was applied to the oocyte to determine VGCC
expression (Fig. 2). Non-treated peak current (amperage, A), activation (ms), and
deactivation tau (ms) values were obtained from oocytes when CaV2.2 expression levels
produced peak currents ≥ 0.5 μA. Peak current (ICa2+) was determined as the most
negative amplitude value from the raw current trace produced by the Transient Test.
Activation and deactivation taus were measured using the exponential standard (zeroshift) curve (Clampfit ver. 9.2, Axon Instruments) by Equation 2:

Equation 2
n

f(t) = ΣAie-τi + C
i=1

Where:
A = Amplitude
τ = time constant
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C = constant y-offset
i = component to be measured

Activation measures the part of the current curve from the start of depolarization
to peak current amplitude and activation tau (η) represents the amount of time required to
open 50% of the channels during membrane depolarization. Deactivation tau measures
the part of the current curve displaying channel activity after membrane depolarization
was removed (repolarization step) and represents the amount of time required to close 50
% of the channels (Clampfit 9.2). Midpoint potentials for activation and steady-state
inactivation were determined by least squares fits of current-voltage relationship from
individual experiments to the Boltzmann equation (Equation 3) using GraphPad Prism.

Equation 3
Y = Bottom + (Top – Bottom)
1+exp (V50 – X)
slope
Treated values (DMSO, PMA and pyrethroid) were obtained from CaV2.2 test
protocols that were run after application of treatments. Only one type of treatment was
applied to each oocyte. Pulse protocols were applied at 4 min and 10 min post treatment
and the raw traces that resulted from each pulse were saved to obtain data values specific
to each time point (Clampex). Raw data values were obtained using Clampfit 9.2. Data
obtained from each time point (min post treatment) were normalized to the non-treated
control using Equation 2.
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Equation 4
Normalized Value =

Treated value
• 100%
Non-treated value

2.8 Statistical Analysis of Data
Analysis of the electrophysiology data was conducted using a combination of
Clampfit 9.2 and Graph Pad Prism (GraphPad Software, Inc, San Diego CA) and
Microsoft Excel (2003 Microsoft Corporation, Seattle WA). Averages and standard error
means were calculated for normalized values from each individual treatment. Averages
were statistically compared to the averaged normalized DMSO control values from each
corresponding time point and step depolarization using a one-way ANOVA with a
Bonferonni Post test comparing selected pairs of treatments (GraphPad Prism, P= 0.05
unless otherwise noted).
For example, peak current (PC) values are recorded as the highest current
amplitude obtained during the Transient Test Protocol. From each oocyte, 11 recordings
are made: no treatment (NT), and one recording per minute for 10 min post treatment.
The 4 min post treatment (4 min) and 10 min post treatment (10 min) recordings are used
for statistical analysis. Each oocyte is treated only once by direct application of the
treatment compound to the recording solution after the NT recording is made. Four min
and 10 min PC recordings are normalized to the NT from the same oocyte from which
they were recorded (Equation 4). Normalized PC recordings are averaged together by
time point and treatment and a standard error of the mean (SEM) was calculated for each
average. Unless otherwise noted, the average and SEM data from each treatment were
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statistically compared to normalized DMSO PC using one-way ANOVA with Bonferonni
Post test.
In the Activation, Inactivation, and Deactivation Test Protocols, recordings are
made at 4 min and 10 min post treatment using 5 mM Ba2+ as the charge carrier. From the
Activation Test Protocol, voltage dependent peak current (mV ± SEM), activation
midpoint potential (mV-1 ± SEM), and voltage-dependent activation (mV-1 ± SEM) data
were collected. Activation midpoint potential and voltage-dependent activation are
reported as V50 act and ηactivation (ms), respectively. The slope and intercept for determining
voltage-dependent activation are reported as ηactivation slope (mV-1 ± SEM) and ηactivation yintercept. From the Inactivation Test Protocol, the inactivation midpoint potential data
were collected and reported as V50inact (mV± SEM). From the Deactivation Test Protocol,
voltage-dependent deactivation data were calculated and reported as the ηdeactivation (ms).
The slope and intercept for determining voltage-dependent deactivation are reported as
ηdeactivation slope (mV-1 ± SEM) and ηdeactivation y-intercept. Data from the Activation,
Inactivation and Deactivation Test Protocols were statistically compared using the
Student’s T-test. Unless otherwise reported, P < 0.05).
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Figure 3: Overview of the method used to express and analyze CaV2.2. α- and β- subunit cDNAs are cloned, amplified and purified
and used to produce cRNAs by in vitro transcription. α- and β-subunit cRNAs are injected in to Xenopus laevis oocytes for
heterologous expression which is verified using two-electrode voltage clamp (TEVC) technique. Using TEVC, CaV2.2 is
subjected to Transient, Activation, Inactivation and Deactivation Test Protocols from which measurements are taken to
determine the transient peak current, activation taus, inactivation taus, deactivation taus, current-voltage relationships,
voltage-dependent peak current, voltage-dependent activation rate, activation midpoint potential, inactivation midpoint
potential and voltage-dependent deactivation rate under control and treated conditions, Values are statistically compared
using either One-way ANOVA with Bonferonni Post Test or Student’s T-test (P < 0.05).
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CaV2.2 and β3 cDNAs obtained for amplification and purification.
CaV2.2 and β3 cRNAs produced by in vitro transcription (Symington 2005)

Xenopus laevis oocytes injected with cRNAs (Shih et al. 1998; Soderlund et al. 2002).

Expression of CaV2.2 verified using the TEVC technique
Transient Test
10 mV

Activation Test

150 ms

40 mV

-80 mV

10 ms

-80 mV

43

Deactivation Test

Inactivation Test
0 mV

2s

50 ms

0 mV

10 ms

100 ms

-80 mV

-120 mV

Measurements taken from CaV2.2 current traces expressed in Xenopus oocytes by TEVC.

Values were normalized to either their respective No Treatment values or DMSO. Steady-state
data was analyzed using one-way ANOVA with Bonferonni post-test was used to determine the statistical
differences between treatments (P<0.05) and voltage-dependent data was statistically analyzed using Ttests (P<0.05).
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Table 2: Types of data endpoints obtained from the Transient, Activation, Inactivation, and Deactivation Test protocols.
Protocol

Endpoints
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Transient

Activation

Inactivation

Deactivation

Transient Peak Current

Voltage-dependent peak

Inactivation MPP

Voltage-dependent

(μAT/μANT x 100)

current (mV)

(mV ± SEM)

deactivation (ηdeactivation)

Activation tau

Activation MPP

ηdeactivation slope

(msecT/msecNT x 100)

(mV ± SEM)

(mV ± SEM)

Inactivation tau
(msecT/msecNT x 100)

Voltage-dependent
activation (ηactivation)

ηdeactivation y-intercept

Deactivation tau

ηactivation slope

(msecT/msecNT x 100)

(mV-1± SEM)

-1

ηactivation y-intercept
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CHAPTER 3
PMA INCREASES TRANSIENT PEAK CURRENT AND CHANGES THE GATING
KINETICS OF CAV2.2

3.1 Results
3.1.1 Steady-state Peak Current
Using the Transient Test Protocol, maximal effects on transient peak current under
steady-state depolarization were observed for wild type CaV2.2 in the presence of DMSO,
PMA and 4α-PMA over the course of a 10 min incubation period (Fig. 4A). PMA
treatment of expressed CaV2.2 phosphorylates the channel due to the activation of PKC.
Under basal conditions in the absence of PMA CaV2.2 is unphosphorylated (Stea et al.,
1995). The presence of PMA at 4 min post treatment caused the largest and most
significant difference in transient peak current (49%) compared to the DMSO control. At
4 min post treatment, transient peak current in the presence of 4α-PMA was significantly
less (-31%) than transient peak current in the presence of PMA. The presence of PMA
caused a significant 40% increase compared to the effect of DMSO on transient peak
current at 10 min post treatment. In the presence of 4α-PMA at 10 min post treatment,
transient peak current was not significantly different from transient peak current in the
presence of DMSO or PMA (Fig. 4B; Table 3).
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Figure 4. The effects of 0.1 % DMSO, the phorbol ester PMA (8 x 10-7 M) and its
enantiomer 4α-PMA (8 x 10-7 M) on relative transient peak current of wild
type CaV2.2 over 10 min. A diamond (♦) indicates significant difference from
DMSO treatment. A circle (●) indicates significant difference from PMA
treatment. The number of eggs (n) used for these treatments are: DMSO (n =
39); PMA (n = 51); 4α-PMA (n = 12). Significance was calculated using Oneway ANOVA with Bonferroni’s Multiple Comparison post test (P<0.05).
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3.1.2 Steady-state Gating Kinetics
Steady-state activation, inactivation and deactivation taus were obtained using the
Transient Test Protocol (Fig. 2). At 4 min post treatment, activation taus in the presence
of PMA were not significantly different from the DMSO control, but at 10 min post
treatment, there was a 21% significant increase in the activation tau in the presence of
PMA (Fig. 5B). In the presence of 4α-PMA at both 4 and 10 min post treatments,
activation taus were not significantly different from DMSO control (Fig. 5A and 5B and
Table 3).
The rate of the inactivation tau did not change significantly in the presence of either
PMA or 4α-PMA at both 4 min and 10 min post treatments (Fig. 5C and 5D and Table 3).
Although not statistically different, the inactivation tau at 4 min post treatment decreased
(-42%) compared to the DMSO control, indicating that there may be a trend that CaV2.2
inactivates faster in the presence of PMA (Fig. 5C).
Steady-state deactivation taus in the presence of PMA at 4 and 10 min post
treatment were increased by 41 and 54%, respectively, compared to the DMSO controls
(Fig. 5E and 5F) indicating that the rate of channel closure after removal of the
depolarization step was slowed. In the presence of 4α-PMA, deactivation taus were not
statistically different compared to those in the presence of DMSO at 10 min post
treatment. However, at 4 min post treatment, 4α-PMA significantly reduced the
deactivation tau 4 min post treatment by 28% compared to the effect of PMA.
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Figure 5. The effects of 0.1 % DMSO, the phorbol ester PMA (8 x 10-7 M) and its
inactive enantiomer 4α-PMA (8 x 10-7 M) on steady-state kinetics of wild type
CaV2.2 at 4 and 10 min post treatment. Activation (A and B), inactivation (C
and D) and deactivation (E and F) taus were normalized to their respective no
treatment controls. The number of eggs (n) used to calculate activation and
deactivation taus at 4 min post treatment were DMSO (n = 38); PMA (n=51);
4α-PMA (n=11) and at 10 min were DMSO (n=38); PMA (n=50); 4α-PMA
(n=12). The number of eggs (n) used to calculate inactivation taus at 4 min
post treatment were DMSO (n=16); PMA (n=16); 4α-PMA (n=3) and at 10
min post treatment, were DMSO (n=12); PMA (n= 17); 4α-PMA (n=4).
Significance was calculated using One-way ANOVAs with Bonferroni’s
Multiple Comparison post test (P<0.05).
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3.1.3 Voltage-dependent Peak Current
The effects of PMA on average voltage-dependent kinetics of CaV2.2 were
determined using current-voltage relationships (I/V curves) obtained using the Activation
Test Protocol (Fig. 2). Voltage-dependent peak current significantly increased by 44%
and 64%, in the presence of PMA compared to the normalized No Treatment and DMSO
controls respectively at 4 min post treatment (Fig. 6A and Table 4). At 10 min post
treatment, voltage-dependent peak current significantly increased in the presence of PMA
by 39% at 10 min post treatment (Fig 6B). The increases in peak current in the presence
of PMA at both 4 and 10 min post treatment are consistent with previous reports (Stea et.
al, 1995). Treatment with 4α-PMA also resulted in significant 24% increase in voltagedependent peak currents at 4 min post treatment (Fig. 6A and Table 4). The difference in
the average voltage-dependent peak current in the presence of PMA and in the presence
of 4α-PMA at 4 min post treatment was not significantly different (Table 4). The effect
of 4α-PMA on peak current at 10 min post treatment was greater but was not significantly
different from the effect of 4α-PMA 4 min post treatment. At 10 min post treatment, the
effect of 4α-PMA treatment on average peak current was not significantly different from
that of the PMA treatment.

3.1.4 Voltage-dependent Gating Kinetics
The activation midpoint potential (V50act) at 4 min post treatment was not altered
by any of the treatments compared to the no treatment control (Table 4). Significant
depolarizing shifts in the activation midpoint potential, however, were observed for both
the DMSO (88%) and 4α-PMA (238%) treatments compared to the no treatment control
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Table 3. The effects of DMSO, PMA and 4α-PMA on CaV2.2 steady-state transient peak current, activation, inactivation and
deactivation taus at 4 and 10 min post treatment.
No Treatment

4 min

51
10 min

Treatment (10-7 M)
DMSO
PMA

4α-PMA

Transient Peak Current
(μAT /μANT x 100)

100 ± 0.0

106.6 ± 3.2

158.9 ± 7.3
♦(49)

110.3 ± 4.0
●(-31)

Activation tau (η)
(msecT /msecNT x 100)

100 ± 0.0

108.4 ± 1.8

104.1 ± 2.2

107.1 ± 2.6

Inactivation tau (η)
(msecT /msecNT x 100)

100 ± 0.0

124.1 ± 12.5

72.24 ± 8.4
♦(-42)

82.9 ± 10.5

Deactivation tau (η)
(msecT /msecNT x 100)

100 ± 0.0

104.0 ± 6.6

146.6 ± 9.1
♦(41)

105.0 ± 8.6
● (-28)

Transient Peak Current
(μAT /μANT x 100)

100 ± 0.0

102.1 ± 4.5

141.9 ± 8.9
♦(40)

114.5 ± 7.8
●(-19)

Activation tau (η)
(msecT /msecNT x 100)

100 ± 0.0

108.4 ± 1.8

131.6 ± 4.8
♦(21)

115.2 ± 4.5

Inactivation tau (η)
(msecT /msecNT x 100)

100 ± 0.0

166.3 ± 32.5

158.9 ± 38.1

99.54 ± 36.5

Deactivation tau (η)
(msecT /msecNT x 100)

100 ± 0.0

104.0 ± 6.6

160.3 ± 13.3
♦(54)

105.4 ± 7.1
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A closed diamond (♦) indicates significant difference from DMSO. A closed circle (●) indicates significant difference from
PMA. Both were determined by one-way ANOVA (P <0.05). Values in parentheses are percent increases or decreases.
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value (Fig. 5D) at 10 min post treatments. The effects of PMA and 4α-PMA treatments on
V50acts were not significantly different from the DMSO treatment or from each other at 10
min post treatment.
Treatments with PMA and 4α-PMA did modify the voltage-dependent
inactivation kinetics compared to the controls (Fig. 6, Table 4). A hyperpolarizing shift in
V50inact is an indication that the channels are inactivating at lower potentials allowing for
decreased Ca2+ influx. At 4 min post treatment, DMSO caused a significant 25%
hyperpolarizing shift in V50inact compared to the no treatment control (Fig. 6E). There was
no significant effect, however, at 10 min post treatment. In the presence of PMA, at 4 min
post treatment significant 40% and 24% hyperpolarizing shifts in the V50inact compared to
the no treatment and DMSO control, respectively, were observed (Fig. 6E, Table 4). The
presence of PMA at 10 min post treatment (Fig. 6F) caused an even greater
hyperpolarizing shift of V50inact compared to no treatment (80%) and DMSO (69%)
values.
4α-PMA did not significantly alter the voltage-dependent inactivation kinetics
compared to the no treatment control, however, a 34% depolarizing shift in V50inact was
observed in the presence of 4α-PMA at 4 min post treatment compared to DMSO
treatment. 4α-PMA did result in significant depolarizing shifts in the V50inact compared to
the PMA treatment at 4 (49%) and 10 (50%) min post treatment (Table 4).
The effects of PMA on the activation and deactivation kinetics of CaV2.2 are
shown in Figure 7 and Table 5. At 4 min post treatment, there were no significant
differences between treatments on the voltage-dependent rates of activation (ηactivation)
(Table 5). In the presence of DMSO at 10 min post treatment, ηactivation was significantly
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Figure 6. Effects of 0.02% DMSO, PMA (1 x 10-7 M) and its inactive analog 4α-PMA (1
x 10-7 M) on voltage-dependent peak current, activation midpoint potential and
inactivation midpoint potential at 4 and 10 min post treatment. (A and B)
Voltage-dependent peak current was normalized to the DMSO control (value of
DMSO treatment normalized to 1). (C and D) Activation midpoint potentials
(V50act) and (E and F) inactivation midpoint potential (V50inact) were determined
by the least-squares fits of the current-voltage relationship from individual
experiments of the Activation and Inactivation Test Protocols using the
sigmoidal dose-response (variable slope) equation. The number of eggs (n)
used for the calculations of voltage-dependent peak currents, and V50act were no
treatment (n= 40); DMSO (n = 19); PMA (n = 17); 4α-PMA (n = 5). (E and F).
The number of eggs (n) used for the calculations of V50inact were no treatment
(n= 30) DMSO (n = 13); PMA (n = 13); 4α-PMA (n = 5). Statistical analysis
was conducted using Student’s T-test (P < 0.05).
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greater than no treatment control by 14% at 30 mV. In the presence of PMA at 10 min
post treatment, there were significant increases in ηactivation values that ranged from 1629% following membrane depolarizations from -20 mV to 30 mV of 16-29% compared
to DMSO control values. Conversely, 4α-PMA caused significant decreases in ηactivation
values at 10 min post treatment that ranged from 21-27% following membrane
depolarization from -30 mV to -10 mV compared to DMSO control values. The ηactivation
values in the presence of 4α-PMA at 10 min post treatment were significantly less than
those following PMA treatment and ranged from 18-37% following membrane
depolarizations from -10 mV to 20 mV.
At 4 min post treatment, ηactivation slope in the presence of DMSO was significantly
different from the no treatment control (Table 6). In the presence of PMA, ηactivation slope
had no significant effect compared to the DMSO control at 4 min post treatment (Figure
7). The ηactivation slope in the presence of 4α-PMA was significantly different compared to
either DMSO or PMA treatments at 4 min post treatment (Table 6).
At 4 and 10 min post treatment, ηactivation y-intercept in the presence of DMSO was
significantly different from the no treatment control treatment (Table 6). The effect of
PMA on ηactivation y-intercept was not significant at 4 min post treatment but was
significantly different at 10 min post treatment from DMSO. The ηactivation y-intercept in
the presence of 4α-PMA was significantly different from both DMSO and PMA at 4 and
10 min post treatments.
The effect of PMA on the voltage-dependent ηdeactivation at 4 min post treatment was
significantly greater than the voltage-dependent ηdeactivation in the presence of DMSO at -40
mV and -30 mV by 29% and 41% respectively (Table 7). The effect of 4α-PMA on
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Table 4. The effects of DMSO, PMA and 4α-PMA on CaV2.2 voltage-dependent peak current, activation and
inactivation midpoint potentials.
No Treatment

4 min

4α-PMA

57

Voltage-dependent
peak current

-0.98 ± 0.01

-0.86 ± 0.07
◊(-12)

-1.41 ± 0.15
◊(44) ♦(64)

-1.22 ± 0.16
◊(24) ♦(42)

Activation MPP
(mV ± SEM)

-1.85 ± 0.43

-1.71 ± 0.65

-0.93 ± 0.75

-3.09 ± 0.40

Inactivation MPP
(mV ± SEM)

-27.73 ± 2.21

-34.40 ± 2.34
◊(25)

-42.62 ± 9.31
◊(-40) ♦(-24)

-21.58 ± 4.21
♦(34) ●(49)

Voltage-dependent

-0.98 ± 0.01

-0.64 ± 0.07

-1.03 ± 0.16

-0.97 ± 0.06

◊(35)

♦(39)

peak current
10 min

Treatment (10-7 M)
DMSO
PMA

Activation MPP
(mV ± SEM)

-1.42 ± 0.52

-0.22 ± 0.74
◊(88)

-1.40 ± 0.47

2.56 ± 1.82
◊(238)

Inactivation MPP
(mV ± SEM)

-25.78 ± 2.28

-27.49 ± 2.62

-46.36 ± 6.01
◊(-80) ♦(-69)

-23.19 ± 4.46
●(50)

An open diamond (◊) indicates significant difference from no treatment. A closed diamond (♦) indicates
significant difference from DMSO. A closed circle (●) indicates significant difference from PMA. Statistical
differences were determined by using Student’s T-test (P <0.05). Values in parentheses are percent increases or
decreases.
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ηdeactivation at 4 min post treatment was significantly less than DMSO treatment by 40% at 30 mV. At 10 min post treatment the presence of DMSO caused significant increases in
ηdeactivation values that ranged from 20-21% following membrane depolarizations from -50
mV to -30 mV.
The ηdeactivation values in the presence of PMA at 10 min post treatment were
significantly greater than those following DMSO treatment and ranged from 44%-86%
following membrane depolarizations from -50 mV to -30 mV. ηdeactivation in the presence of
4α-PMA was not significantly different from either DMSO or PMA treatments at 10 min
post treatment.
The ηdeactivation slope following PMA treatment was significantly greater than the
DMSO control value 4 min (Fig. 7C) and 10 min (Fig. 7D) post treatment (Table 6). In
the presence of 4α-PMA at both the 4 and 10 min post treatment, the ηdeactivation slope was
reduced by -65% and -70%, respectively, compared to the effect of PMA treatment (Table
6). The effect of PMA on the ηdeactivation y-intercept was significantly greater than the
effect of the DMSO control at both 4 min and 10 min post treatments. The ηdeactivation yintercept in the presence of 4α-PMA was significantly less than the effect of PMA at
either 4 or 10 min post treatment by -70% or -49%, respectively (Table 6).

3.2 Discussion
3.2.1 Steady-state peak current
Our results confirm earlier reports that under steady-state conditions, the phorbol
ester PMA is a potent activator of the endogenously expressed PKC in Xenopus oocytes
resulting in altered Cav2.2 currents (Bourinet et al., 1992). PMA is capable of
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Figure 7. Semi-logarithmic plots of the activation tau (A and C) and deactivation tau (C
and D) values resulting from the effects of 0.02% DMSO, PMA (1 x 10-7 M)
and its inactive analog 4α-PMA (1 x 10-7 M) at 4 min (A and B) and 10 min
(C and D) post treatment using the Activation and Deactivation Test Protocols,
respectively. Activation and deactivation tau values are obtained from linear
regression fits to the data. The voltage dependence of activation and
deactivation are represented by slope. The rates of activation and deactivation
are represented by the y-intercept. The number of eggs (n) used for A and C
are: no treatment (n = 41); DMSO (n = 18); PMA (n = 17); 4α-PMA (n = 5).
The number of eggs (n) for B and D are: no treatment (n = 30); DMSO (n =
21); PMA (n = 11); 4α-PMA (n = 5). Statistical analysis was conducted using
Student’s T-test (P < 0.05).
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phosphorylating several different sites on the intracellular loops of CaV2.2 and result in a
variety of altered expression patterns and kinetic properties of this channel (Fang et al.,
2006).
In support of previous findings (Stea et al., 1995), phosphorylated CaV2.2 allowed
an increase of transient Ba2+ peak current under steady-state depolarizing conditions.
The same time-dependent effects of phosphorylated CaV2.2 transient peak current
observed by Stea et. al. (1995) were seen in our assay with a similar run down of Ba2+
currents by the 10 min time point and a maximal effect on peak current occurring at 4
min post treatment.
4α-PMA, the inactive structural analog of PMA, had no effect on Ba2+ influx. A
similar effect of 4α-PMA on transient peak current was also reported by Stea et al.
(1995), but using the R-type Ca2+ channels α1E. Although the Xenopus oocyte system is a
non neuronal heterologous expression system, our findings are consistent with other
studies where neuronal tissue preparations were used to show PMA-activated PKC
increased transient peak current using superior cervical ganglion, and dorsal root
ganglion nerve preparations that also show an increase in peak current in the presence of
PMA-activated PKC(Swartz, 1993). When neuronal cell preparations were treated with
PMA under depolarizing conditions, an increase in whole cell current and
neurotransmitter release was observed (Swartz, 1993; Zhu and Ikeda, 1994; Barrett and
Rittenhouse, 2000; García-Ferreiro et al., 2001). Thus, increases in Ba2+ peak current
from heterologously expressed phosphorylated CaV2.2 in Xenopus oocytes under steady
state depolarizing conditions is consistent with previous reports finding that PMA
activates PKC endogenously expressed within the oocyte allowing phosphorylation of
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Table 5. The effects of DMSO, PMA and 4α-PMA on CaV2.2 voltage-dependent activation (ηactivation).
Test Potential (mV)
-30
-20
-10
0
10
Treatment
-7
tauactivation (ms)
(10 M)

4 min

62
10 min

20

30

No Treatment

5.05 ± 0.41

3.93 ± 0.24

3.10 ± 0.15

2.46 ± 0.09

1.97 ± 0.07

1.58 ± 0.06

1.28 ± 0.05

DMSO

5.09 ± 0.28

4.08 ± 0.20

3.27 ± 0.14

2.64 ± 0.10

2.13 ± 0.07

1.73 ± 0.06

1.41 ± 0.05

PMA

5.78 ± 0.69

4.57 ± 0.46

3.63 ± 0.30

2.90 ± 0.20

2.33 ± 0.13

1.89 ± 0.10

1.53 ± 0.08

4α-PMA

4.25 ± 0.77

3.43 ± 0.52

2.78 ± 0.33

2.28 ± 0.21

1.88 ± 0.14

1.56 ± 0.13

1.31 ± 0.15

DMSO

4.78 ± 0.24

3.91 ± 0.17

3.20 ± 0.13

2.62 ± 0.10

2.15 ± 0.08

1.77 ± 0.07

1.46 ± 0.06

PMA

6.48 ± 0.87

5.07 ± 0.55
♦(29)

4.00 ±0.35
♦(25)

3.18 ± 0.21
♦(21)

2.55 ± 0.13
♦(19)

2.13 ± 0.11
♦(20)

1.70 ± 0.08
♦(16)

4α-PMA

3.51 ± 0.79
♦(-27)

2.96 ± 0.58
♦(-24)

2.52 ± 0.40
♦(-21) ●(-37)

2.16 ± 0.27
●(-18)

1.87 ± 0.17
●(-25)

1.64 ± 0.12
●(-23)

1.45 ± 0.14

An open diamond (◊) indicates significant difference from no treatment. A closed diamond (♦) indicates significant difference from
DMSO. A closed circle (●) indicates significant difference from PMA. Statistical differences were determined by Student’s T-test (P
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<0.05). Values in parentheses are percent increases or decreases.
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CaV2.2 and producing a phosphoform that enhances Ca2+-dependent neurotransmitter
release. (Bourinet et al., 1992; Stea et al., 1995).
Conversely, we observed under steady-state conditions, that the inactive form of
PMA, 4α-PMA, had no significant effect on transient peak current. This confirms
previous studies showing that 4α-PMA does not activate PKC under steady-state
conditions (Castagna et al., 1982; Stea et al., 1995; García-Ferreiro et al., 2001)

3.2.2 Steady-state Gating Kinetics
Apparent phosphorylation of CaV2.2 by PMA-activated PKC induced a slowing
of activation under steady-state depolarization at the end of a 10 min treatment but there
was no change in activation rate at 4 min post treatment when we observed the maximal
effect of PMA on transient peak current. This increase of activation taus following PMA
treatment indicates that phosphorylated CaV2.2 takes more time to open than the
unphosphorylated channel. The increase in activation tau observed at 10 min post
treatment in the presence of PMA was not observed in the presence of DMSO or 4α-PMA
at either the 4 or 10 min post treatments. This slowing of activation tau in the presence of
PMA indicates that phosphorylated CaV2.2 opens at a slower rate than unphosphorylated
CaV2.2. This slowing of the time it takes for the channel to open would, in an in vivo
neuron would decrease Ca2+ influx and decrease subsequent Ca2+-dependent
neurotransmitter release.
Inactivation taus were measured from peak current to end of protocol and are an
indication of how fast or slow CaV2.2 closes under depolarizing conditions. Inactivation
taus of phosphorylated CaV2.2 significantly decreased at 4 min post treatment, indicating
64

Table 6. The effects of DMSO, PMA and 4α-PMA on CaV2.2 voltage-dependent activation and deactivation taus.
ηactvation
Treatment

slope

y-intercept

(10-7 M)

(mV-1 ± SEM)

No Treatment

-0.023 ± 0.001

0.890 ± 0.026

0.012 ± 0.001

1.340 ± 0.074

DMSO

-0.022 ± 0.001

0.944 ± 0.012

0.011 ± 0.002

1.359 ± 0.109

PMA

-0.023 ± 0.001

1.031 ± 0.020

0.020 ± 0.002
♦(45)

2.011 ± 0.104
♦(32)

4α-PMA

-0.019 ± 0.001
♦(-14) ●(-17)

0.804 ± 0.012
♦(-15) ●(-22)

0.007 ± 0.004
●(-65)

1.087 ± 0.262
●(-45)

DMSO

-0.020 ± 0.001

0.951 ± 0.013
◊(7)

0.012 ± 0.002

1.399 ± 0.106

PMA

-0.022 ± 0.001

1.171 ± 0.017
♦(23)

0.023 ± 0.002
♦(85)

2.315 ± 0.106
♦(65)

4α-PMA

-0.013 ± 0.001
♦(-35) ●(-41)

0.737 ± 0.024
♦(-22) ●(-37)

0.007± 0.005
●(-70)

1.182 ± 0.311
●(-49)

(mV-1 ± SEM)

4 min

65
10 min

ηdeactvation
slope
y-intercept

An open diamond (◊) indicates significant difference from no treatment. A closed diamond (♦) indicates significant difference
from DMSO. A closed circle (●) indicates significant difference from PMA. (n) indicates percent increase or decrease.
Student’s T-test (P <0.05).
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that the phosphorylated channel takes less time to inactivate than the unphosphorylated
channel. At 10 min post treatment, we did not observe a significant difference in average
inactivation taus between phosphorylated and unphosphorylated CaV2.2. A decrease in
average inactivation taus means that phosphorylated CaV2.2 takes less time to inactivate
than unphosphorylated CaV2.2. This decrease in inactivation taus is not consistent with
increased Ca2+ influx and neurotransmitter release observed in PMA-treated neuronal
preparations because a fast inactivating channel does not allow for more Ca2+ to enter the
cell.
The significant and pronounced increase in average steady-state deactivation taus
of phosphorylated CaV2.2 is consistent with the data that shows increased Ca2+ influx and
neurotransmitter release in in vivo neuron preparations when treated with PMA (Swartz,
1993; Zhu and Ikeda, 1994; García-Ferreiro et al., 2001). The larger the deactivation taus,
the more time it takes for CaV2.2 to close after the removal of membrane depolarization
and the greater the influx of Ca2+ and neurotransmitter release. Phosphorylated CaV2.2
takes longer to deactivate than unphosphorylated CaV2.2. We know that endogenous
CaV2.2 in in vivo neurons and synaptosomes undergo post translational modifications that
include phosphorylation. The addition of deltamethrin to rat brain synaptosomes resulted
in an increase in Ca2+ influx and subsequent neurotransmitter release. We expect that the
addition of deltamethrin to phosphorylated CaV2.2 expressed in Xenopus oocytes would
result in an even greater increase in Ba2+ influx that is similar to what was observed when
synaptosomes were treated with deltamethrin and Ca2+ enters the synaptosomes.
Fang et al. (2006) demonstrated that there are several residues on CaV2.2 αsubunit that regulate current in the presence of PMA. CaV2.2 mutant S425A had
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Table 7. The effects of DMSO, PMA and 4α-PMA on voltage-dependent deactivation (ηdeactivation).
-80

-70

Test Potential (mV)
-60
-50

-40

-30

Treatment
(10-7M)

4 min

taudeactivation (ms)
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No Treatment

1.53 ± 0.16

1.66 ± 0.13

1.82 ± 0.10

2.02 ± 0.08

2.26 ± 0.08

2.56 ± 0.11

DMSO

1.81 ± 0.21

1.94 ± 0.19

2.10 ± 0.17

2.30 ± 0.16

2.55 ± 0.15

2.85 ± 0.17

PMA

1.64 ± 0.21

1.89 ± 0.15

2.24 ± 0.14

2.69 ± 0.20

3.28 ± 0.32

4.03 ± 0.48

♦(29)

♦(41)

2.27 ± 0.15

2.41 ± 0.05

4α-PMA

2.08 ± 0.66

2.08 ± 0.53

2.11 ± 0.40

2.17 ± 0.28

●(-40)
DMSO

10 min

PMA
4α-PMA

1.86 ± 0.23

1.65 ± 0.09

2.5 ± 0.88

2.03 ± 0.21

2.08 ± 0.13

2.48 ± 0.75

2.23 ± 0.20

2.62 ± 0.19

2.49 ± 0.62
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2.46 ± 0.19

2.74 ± 0.19

3.07 ± 0.19

◊(22)

◊(21)

◊(20)

3.31 ± 0.27

4.20 ± 0.38

5.32 ± 0.54

♦(44)

♦(65)

♦(86)

2.53 ± 0.49

2.60 ± 0.36

2.72 ± 0.23

An open diamond (◊) indicates significant difference from no treatment. A closed diamond (♦) indicates significant difference
from DMSO. A closed circle (●) indicates significant difference from PMA. Statistical differences were determined using
Student’s T-test (P <0.05). Values in parentheses are percent increases or decreases.
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enhanced currents in the presence of PMA. CaV2.2 currents decreased in the presence of
the unchanged S425 isoform. Although they did not show the effect of PMA on the
kinetics of mutant forms of CaV2.2, we would expect that the kinetic profile of S425A
CaV2.2 would be similar to PMA-treated CaV2.2. Some phosphorylation sites had more
of an effect on peak current than others when phosphorylated. Phosphorylated S425
decreased peak current, whereas phosphorylated T422 increased peak current. Even in
the presence of a S425A mutation, significant PMA enhancement of peak current occurs
in the presence of not only phosphorylated T422 but phosphorylated S2108 as well. The
findings show us that it is not just one phosphorylation site or the other that increases or
decreases CaV2.2 current, but multiple phosphorylation sites work together to effect
changes in the response of CaV2.2 to changes in membrane potential. The selective
phosphorylation of these sites, alone and in combination, will be necessary in
determining which sites, when phosphorylated, change the kinetic profile of CaV2.2.

3.2.3 Voltage-dependent peak current
Voltage-dependent peak current of phosphorylated CaV2.2 increased significantly
at both the 4 and 10 min post treatments. A similar effect has been previously reported in
the literature (Stea et al., 1995) and is consistent with enhanced Ca2+ influx and
neurotransmitter release. Voltage-dependent peak current of phosphorylated CaV2.2 also
underwent a 10 mV hyperpolarizing shift from 10 mV to 0 mV. This shift means that
under phosphorylating conditions, 50% of the channels are opening at lower levels of
membrane depolarization than they would have in their unphosphorylated state.
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Unlike under steady-state depolarization, voltage-dependent peak current in the
presence of 4α-PMA is significantly increased compared to our No Treatment control.
This was an unexpected result given that 4α-PMA is considered an inactive analog to
PMA and has no effect on CaV2.2 peak current under steady-state conditions presented
here and elsewhere (Stea et al., 1995; Barrett and Rittenhouse, 2000; García-Ferreiro et
al., 2001). The effect of 4α-PMA on CaV2.2 voltage-dependent peak current, however, is
not significantly different from the effect of PMA on voltage-dependent peak current.
Thus, it is possible, that the increase in voltage-dependent peak current observed in the
presence of 4α-PMA may be due to differential phosphorylation of PKC activity. It is
possible that 4α-PMA does activate PKC, but the spectrum of phosphorylation activity of
4α-PMA-activated PKC may not be as broad as PMA-activated PKC would be. For
example, S425 on the I-II intramembrane loop has been reported to down regulate CaV2.2
activity when phosphorylated and 4α-PMA-activated PKC could be selectively not
phosphorylating S425. Another possibility could be that 4α-PMA-activated PKC could be
selectively phosphorylating T422, a site that has been shown to increase voltagedependent peak current (Fang et al., 2006; Symington et al., 2007a).

3.2.4 Voltage-dependent Gating Kinetics
The V50acts of phosphorylated CaV2.2 were not significantly different from the
DMSO solvent control. We expected that with increases in Ba2+ influx via
phosphorylated CaV2.2, the V50act would be hyperpolarized. A hyperpolarized channel
means that 50% of the channels will activate at depolarization levels lower than
unphosphorylated CaV2.2 thus making the channel more sensitive to changes in
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membrane potential.
Significantly hyperpolarized V50inacts in the presence of PMA indicate that CaV2.2
was more sensitive to undergoing inactivation at smaller changes in membrane potential.
The increased sensitivity to small changes in membrane potential is inconsistent with
increase neurotransmitter release observed when nerve cell preparations are treated with
PMA (Stea et al., 1995; García-Ferreiro et al., 2001). Our data is consistent, however,
with a previous study in which PMA caused a significant 20 mV hyperpolarizing shift in
V50inact (we reported a significant 19 mV shift compared to DMSO control) (GarcíaFerreiro et al., 2001).
We have reported the average voltage-dependent rate of activation (ηactivation) of
non-treated CaV2.2 to be 3.10 ± 0.15 ms at 10 mV. This ηactivation at is nearly identical with
the ηactivation reported by Lin et al. (1997) using heterologous expression of CaV2.2 in
Xenopus oocytes. The presence of PMA or 4α-PMA did not have a significant effect on
the rates of activation (ηactivation) at 4 min post treatment in the range of -30 mV to 30 mV
indicating that the voltage-dependent rates of activation neither increased nor decreased
at this time (Table 5). However, at 10 min post treatment, PMA caused a significant
increase in ηactivation at -20 mV, -10 mV, 0 mV, 10 mV, 20 mV and 30 mV compared to
DMSO. These increases in ηactivation mean that phosphorylated CaV2.2 was taking more
time to activate under as the channel underwent increasing levels of depolarization. The
22% increase in ηactivation means that it took CaV2.2 22% longer to activate when
phosphorylated. Compared to the presence of PMA at 10 min post treatment, 4α-PMA
treated CaV2.2 produced a channel that activated at a faster rate, which was, as expected,
not significantly different compared to the DMSO control.
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We observed that under steady-state depolarization, phosphorylated CaV2.2
required more time to activate at 10 min post treatment. Similarly, we have shown that
ηactivation of phosphorylated CaV2.2 also increases significantly at 10 min post treatment
and the time required to activate the channel remains significantly greater than the time
required to activate unphosphorylated CaV2.2 under voltage-dependent conditions in the
range of -20-30mV.
Steady-state inactivation for phosphorylated CaV2.2 was not significantly altered
compared to steady-state inactivation of unphosphorylated CaV2.2. Here, we see that
phosphorylated CaV2.2 is activating slower and the slowing of activation remains at
increasing levels of depolarization, phosphorylated CaV2.2 does not take longer to
inactivate. This slowing rate of activation and the unchanged rate of inactivation under
phosphorylating conditions does not support the observation that phosphorylation
increases Ba2+ and that the addition of PMA to neuronal cell cultures enhances Ca2+
influx. Thus, we can conclude that phosphorylation of CaV2.2 does not increase Ba2+ or
Ca2+ through activation or inactivation gating kinetics of the channel.
In the presence of PMA, ηdeactivation was prolonged at 4 min post treatment at -40
mV and -30 mV (Table 7). This prolongation of the time it takes for CaV2.2 to close after
the removal of the membrane depolarization pulse corresponds with increased Ca2+ influx
and neurotransmitter release because more Ca2+ is able to flow through the channel in the
time it takes for it to completely deactivate. Although ηdeactivation increased in the presence
DMSO at 10 min post treatment at -50 mV, -40 mV and -30 mV compared to no
treatment, PMA still further increased ηdeactivation significantly more than the effect of
DMSO at the same potentials. The increase in ηdeactivation at -50 mV, -40 mV, and -30 mV
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means that CaV2.2 is taking more time to deactivate at higher levels of depolarization,
allowing more Ca2+ to influx, in the in vivo neuron would correspond to an increase in
neurotransmitter release.
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CHAPTER 4
EFFECTS OF DELTAMETHRIN ON PMA-ACTIVATED PKC-PHOPHORYLATED
CAV2.2

4.1 Results

4.1.1 Transient Peak Current
Using the Transient Test Protocol, maximal effects on transient peak current were
observed for wild type CaV2.2 in the presence of deltamethrin, PMA + deltamethrin, and
4α-PMA + deltamethrin during a 10 min incubation period (Fig. 8A). The presence of
deltamethrin significantly reduced transient peak current compared to the effect of
DMSO at 4 min (-18%) and 10 (-29%) min post treatment. The presence of PMA +
deltamethrin significantly increased transient peak current compared to DMSO by 69% at
4 min and 82% at 10 min post treatment.
The presence of PMA + deltamethrin significantly increased transient peak
current by 107% at 4 min and 156% at 10 min post treatment compared to the effect of
deltamethrin (Fig 8A). At 4 min post treatment, transient peak current in the presence of
4α-PMA + deltamethrin was significantly less (-42%) than transient peak current in the
presence of PMA + deltamethrin, but was significantly greater (19%) than transient peak
current in the presence of deltamethrin alone. At 10 min post treatment, the effect of 4αPMA + deltamethrin on peak current was 47% less than the effect of PMA +
deltamethrin.
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Figure 8. The effects of 0.1 % DMSO, deltamethrin (2 x 10-7 M), PMA (8 x 10-7 M) +
deltamethrin (2 x 10-7 M) and 4α-PMA (8 x 10-7 M) + deltamethrin (2 x 10-7
M) on transient peak current of wild type CaV2.2 over a 10 min incubation
period. Significance was calculated using one-way ANOVA with Bonferroni’s
multiple comparison post test (P<0.05). A diamond (♦) indicates significant
difference from DMSO treatment. A square (■) indicates significant
difference from deltamethrin treatment. A circle (●) indicates significant
difference from PMA treatment. The numbers of eggs (n) used for these
treatments are as follows: DMSO (39); deltamethrin (18); PMA +
deltamethrin (9); 4α-PMA + deltamethrin (10).

91

300

DMSO
M
PMA + M
4-PMA + M

200




























150

*



*





*



*





















100
50
0

0 1 2 3 4 5 6 7 8 9 10

Time (min)
300

4 min
10 min

250

B.


200



150


100




50

ΔM
+

ΔM

92

4α

-P

M

A

A

+

ΔM
PM

SO

0

DM

Relative Transient Peak Current
(% of Control)

250

A.



4.1.2 Steady-state Gating Kinetics
In the presence of deltamethrin, steady-state activation taus were not significantly
different from the DMSO controls at either the 4 min (Fig. 4A) or 10 min (Fig. 4B) post
treatments. At 4 min post treatment, the PMA + deltamethrin treatment had no significant
effect on activation taus compared to DMSO. The presence of PMA + deltamethrin
significantly increased activation taus at 10 min post treatment (Fig 9B) compared to the
effects of DMSO (27%) and deltamethrin (28%) (Table 8). The presence of 4α-PMA +
deltamethrin had no significant effect on activation taus at either the 4 min or 10 min post
treatments.
Steady-state inactivation taus were not significantly changed in the presence of
deltamethrin following either 4 min (Fig. 9C) or 10 min (Fig. 9D) post treatments. At 4
min post treatment, average steady-state inactivation taus were significantly reduced by
53% in the presence of PMA + deltamethrin compared to DMSO and reduced by 52%
compared to deltamethrin (Fig. 9D). In the presence of PMA + deltamethrin, steady-state
inactivation taus were not significantly different from DMSO or PMA (Table 3) at 10 min
post treatment, but were significantly less than steady-state inactivation taus in the
presence of deltamethrin by 62% (Table 6).
There were no significant effects of deltamethrin on steady-state deactivation taus
following either 4 min or 10 min post treatments compared to DMSO (Fig. 9E and F). At
4 and 10 min post treatment, the presence of PMA + deltamethrin significantly increased
average deactivation taus by 79% and 54%, respectively, compared to DMSO (Fig. 9E).
Although the difference in deactivation taus in the presence of PMA (Table 3) and PMA +
deltamethrin were not significantly different at 4 min post treatment, the effect of PMA +
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Figure 9. The effects of 0.1 % DMSO, deltamethrin (2 x 10-7 M), PMA (8 x 10-7 M) +
deltamethrin (2 x 10-7 M) and 4α-PMA (8 x 10-7 M) + deltamethrin (2 x 10-7
M) on steady-state kinetics of wild type CaV2.2 at 4 min and 10 min post
treatment. Activation (A and B), inactivation (C and D) and deactivation (E
and F) taus were normalized to their respective No Treatment controls. The
number of eggs (n) used for activation and deactivation taus at 4 min post
treatment were DMSO (38); deltamethrin (25) PMA + deltamethrin (10); 4αPMA + deltamethrin (9). The number of eggs (n) used for inactivation tau
were DMSO (16); deltamethrin (19) PMA + deltamethrin (10); 4α-PMA +
deltamethrin (9). Significance was determined by one-way ANOVA with
Bonferroni’s multiple comparison post test (P <0.05). Symbols followed by
asterisks (*) indicate that P <0.1.
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deltamethrin on deactivation taus was greater than the effect of PMA (Table 3).
Deactivation taus in the presence of 4α-PMA+ deltamethrin at 4 min post treatment were
37% less than the effect of PMA + deltamethrin but deactivation taus were not
significantly altered at 10 min post treatment.

4.1.3 Voltage-dependent Peak Current
The presence of deltamethrin caused significant decrease (-12%) in maximal
voltage-dependent peak current compared to No Treatment at 10 min post treatment (Fig.
10B and Table 9). However, the decrease in maximal voltage-dependent peak current in
the presence of deltamethrin was not significantly different from DMSO treatment at 10
min post treatment (Table 9). The presence of PMA + deltamethrin significantly increased
maximal voltage-dependent peak current compared to No Treatment (47%), DMSO
treatment (70%) and deltamethrin (46%) at 4 min post treatment. At 10 min post
treatment, maximal voltage-dependent peak current in the presence of PMA +
deltamethrin was reduced by -26% compared to the maximal peak current at 4 min post
treatment. Compared to DMSO treatment at 10 min post treatment (Fig. 4), maximal
voltage-dependent peak current in the presence of PMA + deltamethrin was significantly
greater by 21%. The presence of 4α-PMA + deltamethrin significantly reduced maximal
voltage-dependent peak current at 4 min post treatment by -16% compared to No
Treatment and by -32% compared to 4α-PMA treatment. Maximal voltage-dependent
peak current in the presence of 4α-PMA + deltamethrin was significantly less than the
effect of PMA + deltamethrin treatment at 4 min post treatment by -43%. At 10 min post
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Table 8. The effects of DMSO, deltamethrin, PMA + deltamethrin and 4α-PMA + deltamethrin on CaV2.2 steady-state transient
peak current, activation, inactivation and deactivation taus.

DMSO

4 min

97
10 min

Treatment (10-7 M)
PMA +
Deltamethrin
deltamethrin

4α-PMA +
deltamethrin

Transient Peak Current
(μAT /μANT x 100)

106.6 ± 3.2

87.4 ± 5.1
♦(-18)

180.6 ± 15.3
♦(69) ■(107)

104.2 ± 5.0
●(-42) ■(19)

Activation tau (η)
(msecT /msecNT x 100)

108.4 ± 1.8

100.9 ± 4.2

101.3 ± 3.8

102.7 ± 3.4

Inactivation tau (η)
(msecT /msecNT x 100)

124.1 ± 12.5

123.8 ± 10.7

58.8 ± 6.5
♦(-53) ■(-52)

97.2 ± 11.2

Deactivation tau (η)
(msecT /msecNT x 100)

104.0 ± 6.6

125.6 ± 13.9

186.5 ± 42.5
♦*(79)

102.5 ± 5.1
□(-37)

Transient Peak Current
(μAT /μANT x 100)

102.1 ± 4.5

72.6 ± 15.8
♦(-29)

185.8 ± 5.6
♦(82) ■(156)

97.7 ± 9.1
●(-47)

Activation tau (η)
(msecT /msecNT x 100)

108.4 ± 1.8

107.7 ± 4.3

135.8 ± 15.3
♦(27) ■(28)

105.5 ± 5.4

Inactivation tau (η)
(msecT /msecNT x 100)

166.3 ± 32.5

243.7 ± 40.8

92.8 ± 12.5
■(-62)

198.7 ± 52.5

Deactivation tau (η)
(msecT /msecNT x 100)

104.0 ± 6.6

129.6 ± 15.3

160.3 ± 17.2
♦*(54)

100.6 ± 6.3
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All values are normalized to the no treatment control (100.0). A closed diamond (♦) indicates significant difference from
DMSO. A closed square (■) indicates significant difference from deltamethrin. A closed circle (●) indicates significant
difference from PMA. An open square (□) indicates significant difference from PMA + deltamethrin. The values in parentheses
(n) are percent increases or decreases. Significance was determined by One-way ANOVA with Bonferroni’s multiple
comparison post test (P <0.05). Asterisks (*) indicates the P < 0.10.
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treatment, deltamethrin treatment caused a significant -12% reduction in peak current
compared to No Treatment, but the effect was not significantly different from the effect
of DMSO (Table 4). PMA + deltamethrin treatment increased maximal peak current by
21% compared to DMSO. 4α-PMA + deltamethrin treatment significantly decreased peak
current by -27% compared to No Treatment at 10 min post treatment. Compared to PMA
+ deltamethrin treatment at 10 min post treatment, 4α-PMA + deltamethrin treatment
significantly reduced peak current by 33%. The presence of 4α-PMA + deltamethrin
treatment significantly reduced peak current by -26% compared to 4α-PMA treatment at
10 min post treatment.

4.1.4 Voltage-dependent Gating Kinetics
The Activation Protocol was used to measure the midpoint activation potential
(V50act) in the presence of deltamethrin, PMA + deltamethrin and 4α-PMA + deltamethrin
(Fig. 10C and D; Table 9). The presence of deltamethrin resulted in no significant effect
on V50act compared to DMSO at either 4 or 10 min post treatments. In the presence of
PMA + deltamethrin, V50act underwent significant 56% and 117% hyperpolarizing shifts
at 4 and 10 min post treatments, respectively compared to the V50act in the presence of
PMA (Table 9). In the presence of 4α-PMA + deltamethrin at 4 min post treatment,
significant depolarizing shifts in the V50act compared to DMSO (175%), deltamethrin
(171%), and 4α-PMA (142%) (Table 9) were apparent.
In the presence of deltamethrin at 4 and 10 min post treatment, there was no
significant effect on the inactivation midpoint potential (V50inact) compared to DMSO
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Figure 10. Effects of 0.02% DMSO, deltamethrin (1 x 10-7 M), PMA (1 x 10-7 M) +
deltamethrin (1 x 10-7 M) and 4α-PMA (1 x 10-7 M) + deltamethrin (1 x 10-7
M) on voltage-dependent peak current, activation midpoint potential and
inactivation midpoint potential at 4 min and 10 min post treatment. (A and B)
Voltage-dependent peak current was normalized to the DMSO control (value
of DMSO treatment normalized to 1). (C and D) Activation midpoint
potentials and (E and F) inactivation midpoint potentials were determined by
the least-squares fits of the current-voltage relationship from individual
experiments of the Activation and Inactivation Test Protocols using the
sigmoidal dose-response (variable slope) equation. Significance was
calculated using Student’s T-test (P < 0.05). The number of eggs (n) used for
A-D treatments are DMSO (19); deltamethrin (5); PMA + deltamethrin (5);
4α-PMA + deltamethrin (5). (E and F) The number of eggs (n) used for E-F
treatments are DMSO (12); deltamethrin (5); PMA + deltamethrin (5); 4αPMA + deltamethrin (5). Significance was calculated using Student’s T-test
(P<0.05).
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(Table 9). The presence of PMA + deltamethrin at 4 min post treatment caused a
hyperpolarizing shift in the V50inact that was significantly different from both DMSO
(28%) and deltamethrin (71%). At 10 min post treatment, the presence of PMA +
deltamethrin caused a significant 63% hyperpolarizing shift in V50inact compared to
DMSO and a significant 111% hyperpolarizing shift in V50inact compared to PMA. The
presence of 4α-PMA + deltamethrin caused a significant 29% depolarizing shift in V50inact
compared to DMSO at 4 min post treatment.
Voltage-dependent rate constants for activation (ηactivation) are shown in Table 10.
Deltamethrin treatment resulted in no significant effect on ηactivation at either 4 or 10 min
post treatment compared to DMSO. PMA + deltamethrin treatment resulted in no
significant effect compared to DMSO at 4 min post treatment. However, PMA +
deltamethrin significantly increased ηactivation by 33% (-20 mV), 28% (-10 mV), 20% (0
mV), 23% (10 mV) 21% (20 mV) and 20% (30 mV), respectively, at 10 min post
treatment compared to the DMSO. The presence of deltamethrin on 4α-PMA-treated
CaV2.2 had the unexpected effect of significantly increasing ηactivation at-30 mV by 90%
and at -20 mV and -10 mV by 33% compared to DMSO. At -30 mV, the 4α-PMA +
deltamethrin treatment increased ηactivation by 67% compared to deltamethrin alone.
ηactivation in the presence of 4α-PMA + deltamethrin was significantly less than ηactivation in
the presence of PMA + deltamethrin at 20 mV and 30 mV by 16% and 21%, respectively.
At 4 min post treatment, ηactivation slope in the presence of deltamethrin was not
significantly different from DMSO (Fig. 11A). The ηactivation slope at 10 min post
deltamethrin treatment, however, was significantly increased by 30% compared to
DMSO control (Fig. 11C and Table 11). In the presence of PMA+ deltamethrin at 4 min
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Table 9. The effects of DMSO, deltamethrin, PMA + deltamethrin and 4α-PMA + deltamethrin on voltage-dependent peak
current, activation and inactivation midpoint potentials.
Treatment (10-7 M)

Voltage-dependent

4α-PMA +
deltamethrin

No Treatment

DMSO

Deltamethrin

-0.99 ± 0.01

-0.86 ± 0.07

-1.00 ± 0.04

-1.46 ± 0.19
◊(47) ♦(70)
■*(46)

-0.83 ± 0.08
◊(-16) ○*(-43)
Δ*(-32)

-1.83 ± 0.35

-2.09 ± 0.29
●(-56)

1.30 ± 0.61
♦(175) ■(171)
Δ(142)

4 min
◊(-12%)

peak current
Activation MPP

PMA +
deltamethrin

-1.47 ± 0.33

-1.71 ± 0.65

(mV ± SEM)
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Inactivation MPP
(mV ± SEM)

-27.35 ± 5.01

-34.38 ± 2.34
◊(25)

-25.73 ± 2.47

-44.07 ± 3.45
♦(-28) ■(-71)

-24.55 ± 3.06
♦(29)

Voltage-dependent

-0.99 ± 0.01

-0.64 ± 0.07

-0.87 ± 0.05

-1.08 ± 0.17

◊(-35)

◊(-12)

♦(21)

-0.72 ± 0.08
◊(-27) ○*(-33)
Δ(-26)

10 min
peak current
Activation MPP
(mV ± SEM)

-1.47 ± 0.33

-0.22 ± 0.74
◊(88)

-3.44 ± 0.69

-3.04 ± 0.61
●(-117)

0.85 ± 0.72
■(124)

Inactivation MPP
(mV ± SEM)

-27.02 ± 1.10

-28.79 ± 0.67

-21.21 ± 2.16

-44.69 ± 1.56
♦(-63) ■(-111)

-20.07 ± 0.79

An open diamond (◊) indicates significant difference from No Treatment. A closed diamond (♦) indicates significant difference
from DMSO. A square (■) indicates significant difference from deltamethrin. A circle (●) indicates significant difference from
PMA. A triangle (Δ) indicates significant difference from 4α-PMA. A open circle (○) indicates significant difference from
PMA + ΔM. The values in parentheses (n) are percent increases or decreases. Significance was calculated using Student’s T103

test (P<0.05). Symbols followed by an asterisk (*) indicate that the significance level was P < 0.1.

104
104

post treatment, ηactivation slope was reduced by 14% compared to DMSO. 4α-PMA +
deltamethrin treatment significantly reduced ηactivation slope by 35% compared to DMSO
and by 38% compared to deltamethrin at 10 min post treatments.
Deltamethrin and PMA + deltamethrin treatments resulted in no significant effects
on ηactivation y-intercept of CaV2.2 at 4 min post treatment but PMA + deltamethrin
treatment significantly increased the ηactivation y-intercept compared to DMSO by 23% at
10 min post treatment. The ηactivation y-intercept was significantly reduced (-16%) by the
4α-PMA + deltamethrin treatment compared to DMSO at 4 min post treatment.
The 4 min deltamethrin treatment caused a significant increase (15%) in the
voltage-dependent rate constant for deactivation (ηdeactivation) at -30 mV (Table 12). At 10
min post deltamethrin treatment, there was no effect on ηdeactivation. PMA + deltamethrin
treatment also produced no significant effect on ηdeactivation at either 4 or 10 min post
treatment. The 4 min post 4α-PMA + deltamethrin treatment caused significant
reductions in ηdeactivation values at -60 mV (40%), -50 mV(32%), -40 mV(35%) and -30
mV (36%) compared to their respective DMSO ηdeactivation values. The 10 min post 4αPMA + deltamethrin treatment, also reduced the ηdeactivation values by 43% (-60 mV), 36%
(-50 mV), 39% (-40 mV) and 41% (-30 mV). Deltamethrin had no significant effect on
ηdeactivation slope at either the 4 or 10 min post treatments compared to DMSO (Table 11).
The effect of PMA + deltamethrin on ηdeactivation slope was significantly reduced by 50%
compared to PMA at 4 min post treatment and by 30% at 10 min post treatment (Table
11).
Deltamethrin and PMA + deltamethrin resulted in no significant effects on the
ηdeactivation y-intercepts at either 4 or 10 min post treatments compared to DMSO. The
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Figure 11. Semi-logarithmic plots of the activation tau (ηactivation) and deactivation tau
(ηdeactivation) values resulting from the effects of DMSO, deltamethrin (1 x 10-7
M), PMA (1 x 10-7 M) + deltamethrin (1 x 10-7 M) and 4α-PMA (1 x 10-7 M)
+ deltamethrin (1 x 10-7 M) + at 4 min (A and B) and 10 min (C and D) post
treatment using the Activation Protocol (A and C) and the Deactivation
Protocol (B and D), respectively. Activation tau and deactivation tau rate
constants were obtained from linear regression fits to the data. The number
of eggs (n) used for panels A and C are DMSO (n = 18); deltamethrin (n =
5); PMA + deltamethrin (n = 5); 4α-PMA + deltamethrin (n = 5). The
number of eggs (n) used for panels B and D are DMSO (n = 18);
deltamethrin (n = 5); and PMA + deltamethrin (n = 5); 4α-PMA +
deltamethrin (n = 5). Significance was calculated using Student’s T-test
(P<0.05).
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ηdeactivation y-intercept was reduced by 31% following the 4 min PMA + deltamethrin
treatment compared to PMA (Table 6). The effects of PMA + deltamethrin treatment on
the ηdeactivation y-intercepts were significantly less (-38% at 4 min and 44% at 10 min) than
DMSO. 4α-PMA + deltamethrin treatment significantly reduced ηdeactivation y-intercept
compared to deltamethrin by at both 4 (-38%) and 10 min (-52%) min post treatments
(Table 6).

4.2 Discussion
4.2.1. Transient peak current
It is known that CaV2.2 undergoes post-translational modifications that include
phosphorylation (Swartz, 1993; Swartz et al., 1993; Zhu and Ikeda, 1994). There are five
sites located on the intracellular loops of CaV2.2 capable of being phosphorylated by
PKC and it has been shown that, depending on which sites are phosphorylated, CaV2.2
will exhibit different functional characteristics (Fang et al., 2006). When CaV2.2 is
phosphorylated by PMA-activated PKC, there is no control over which of the available
sites are phosphorylated. The uncertainty of which sites are actually phosphorylated or
not may have produced different phosphoforms from those produced in the synaptosomes
and via mutagenesis and may have contributed to the different results obtained in the
current study versus those obtained previously using different protocols (Symington and
Clark, 2005; Symington et al., 2007a).
Nevertheless, the current data support, in part, previous findings, which suggest
that deltamethrin modifies phosphorylated CaV2.2 and increases channel conductance.
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Table 10. The effects of DMSO, deltamethrin, PMA + deltamethrin and 4α-PMA + deltamethrin on voltage-dependent activation
(ηactivation).
-30

-20

Test Potential (mV)
0

-10

10

20

30

Treatment
(10-7M)

tauactivation (ms)
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No Treatment

5.05 ± 0.41

3.93 ± 0.24

3.10 ± 0.15

2.46 ± 0.09

1.97 ± 0.07

1.58 ± 0.06

1.28 ± 0.05

DMSO

5.09 ± 0.28

4.08 ± 0.20

3.27 ± 0.14

2.64 ± 0.10

2.13 ± 0.07

1.73 ± 0.06

1.41 ± 0.05

Deltamethrin

4.80 ± 0.36

3.90 ± 0.25

3.17 ± 0.17

2.58 ± 0.12

2.10 ± 0.09

1.72 ± 0.08

1.40 ± 0.08
◊(10)

PMA +
deltamethrin

4.75 ± 0.39

3.96 ± 0.29

3.30 ± 0.21

2.75 ± 0.15

2.30 ± 0.11

1.92 ± 0.09

1.60 ± 0.07

4α-PMA +
deltamethrin

4.38 ± 0.41

3.63 ± 0.25

3.02 ± 0.15

2.52 ± 0.09

2.10 ± 0.09

1.76 ± 0.11

1.48 ± 0.13

DMSO

4.78 ± 0.24

3.91 ± 0.17

3.20 ± 0.13

2.62 ± 0.10

2.15 ± 0.08

1.77 ± 0.07

1.46 ± 0.06

Deltamethrin

5.42 ± 0.32

4.34 ± 0.21

3.47 ± 0.13

2.78 ± 0.08

2.23 ± 0.06

1.79 ± 0.06

1.44 ± 0.06

10 min PMA +
deltamethrin

5.07 ± 0.53

5.19 ± 0.99
♦ (33)

4.11 ± 0.58
♦(28)

3.28 ± 0.3
♦(20)

2.64 ± 0.13
♦(23) ■(18)

2.14 ± 0.03
♦(21) ■(20)

1.75 ± 0.07
♦(20) ■(22)

4α-PMA +
deltamethrin

9.07 ± 2.31
♦(90) ■(67)

5.83 ± 1.24
♦(33)

4.26 ± 0.71
♦(33)

3.16 ± 0.37

2.36 ± 0.16

1.79 ± 0.06
□(-16)

1.38 ± 0.09
□(-21)

4 min

109

An open diamond (◊) indicates significant difference from No Treatment. A closed diamond (♦) indicates significant difference
from DMSO. A square (■) indicates significant difference from deltamethrin. An open square (□) indicates significant difference
from PMA + deltamethrin. The values in parentheses (n) are percent increases or decreases. Significance was calculated using
Student’s T-test (P<0.05).
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As expected, when deltamethrin was applied to heterologously expressed
unphosphorylated wild type CaV2.2 under steady-state conditions, peak current
decreased. This finding was the same as that initially reported by Symington and Clark
(2005). When deltamethrin was applied to CaV2.2 that had been phosphorylated in a
PMA-activated PKC-dependent manner under steady-state conditions, however, peak
current significantly increased (Alves et al., 2009).
The decrease in peak CaV2.2 current observed when deltamethrin was applied to
unphosphorylated CaV2.2 was inconsistent with biochemical studies which showed that
dosing with deltamethrin significantly increased neurotransmitter release from rat brain
synaptosomes (Symington et al., 2007b). Dosing live rats with deltamethrin also
increased neurotransmitter release (Aldridge et al., 1978; Hossain et al., 2004). The
increase in neurotransmitter release was, therefore, consistent with the CS-syndrome
observed during deltamethrin poisoning. The decrease in peak current caused by the
dosing of deltamethrin on unphosphorylated CaV2.2 under steady state conditions is
inconsistent with previous reports and led us to conclude that post translational
modifications, which are not readily available in the non-neuronal Xenopus oocyte
system, but are available in the in vivo system, may play a role in how deltamethrin acts
upon the channel.
A permanently phosphorylated channel was created by site-directed mutagenesis,
which converted a threonine at site 422 (T422) to a glutamate (T422E). This permanently
phosphorylated channel, when heterologously expressed in Xenopus oocytes and treated
with deltamethrin, mimicked the effect of deltamethrin in the live rat in vivo system, and
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Table 11. The effects of DMSO, deltamethrin, PMA+ deltamethrin and 4α-PMA + deltamethrin on the slopes and intercepts of
CaV2.2 voltage dependent activation and deactivation taus.
ηactvation
Treatment

slope

(10-7 M)

(mV-1 ± SEM)

ηdeactvation
slope
y-intercept

y-intercept

(mV-1 ± SEM)

DMSO

-0.022 ± 0.001

0.944 ± 0.012
◊(6)

0.011 ± 0.002

1.359 ± 0.109

Deltamethrin

-0.023 ± 0.002

0.905 ± 0.046

0.015 ± 0.002

1.630 ± 0.115

4 min PMA +
deltamethrin

-0.019 ± 0.001
♦(14)

0.995 ± 0.026

0.010 ± 0.002
●(-50)

1.381 ± 0.103
●(-31)

-0.020 ± 0.001

0.794 ± 0.0180

0.008 ± 0.003

0.844 ± 0.180
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4α-PMA +

♦(-16)

deltamethrin
DMSO

-0.020 ± 0.001

Deltamethrin

-0.026 ± 0.002
♦(30)

PMA +
deltamethrin

-0.021 ± 0.001
■(19)

4α-PMA +
deltamethrin

-0.013 ± 0.001
♦(-35) ■(-50)

0.951 ± 0.013
◊(7)

♦(-38) ■(-48)
0.012 ± 0.002

1.399 ± 0.106

0.015 ± 0.002

1.630 ± 0.105

1.168 ± 0.022
♦(23) ■(18)

0.016 ± 0.002
●(-30)

1.770 ± 0.112
●(-24)

0.763 ± 0.021
♦(-20) ■(-23)

0.007 ± 0.004

0.784 ± 0.217
♦(-44) ■(-52)

0.987 ± 0.054

10 min

An open diamond (◊) indicates significant difference from No Treatment. A closed diamond (♦) indicates significant
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difference from DMSO. A square (■) indicates significant difference from deltamethrin. A circle (●) indicates
significant difference from PMA. The values in parentheses (n) are percent increases or decreases. Significance was
calculated using Student’s T-test (P<0.05).
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in intact synaptosomes by significantly increasing Ba2+(Ca2+), current (Symington et al.,
2007a). To observe the effects of deltamethrin on wild type CaV2.2 under
phosphorylating conditions, PMA was used to induce endogenous PKC activity in the
Xenopus heterologous expression system with the expectation that PKC phosphorylation
activity would not be selective. Under steady-state depolarization, PMA + deltamethrin
treatment significantly increased Ba2+ current compared to DMSO and deltamethrin
treatments at both 4 and 10 min post treatment. The increase in peak current via PMAactivated PKC-dependent phosphorylated CaV2.2 in the presence of deltamethrin
supports the hypothesis that phosphorylation enhances the action of deltamethrin on
CaV2.2.

4.2.2 Steady-state Gating Kinetics
Deltamethrin treatment produced no significant effect on steady-state activation of
CaV2.2, but PMA + deltamethrin significantly increased activation taus at 10 min post
treatment compared to DMSO and deltamethrin alone. The increase in steady-state
activation taus indicates that phosphorylated CaV2.2, when treated with deltamethrin, is
slow to activate completely causing a reduction in Ba2+ influx. This delay in activation is
consistent with a study by Symington and Clark (2005), in which steady-state activation
taus of CaV2.2 were significantly increased in the presence of deltamethrin. As expected,
the treatment of 4α-PMA + deltamethrin resulted in no effect on steady-state activation.
The reduction in Ba2+ (or Ca2+) influx due to the slowing of steady-state activation
of phosphorylated CaV2.2 activation in the presence of deltamethrin is not consistent with
increased neurotransmitter release. When applied to synaptosomes, deltamethrin caused
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Table 12. The effects of DMSO, deltamethrin, PMA + deltamethrin and 4α-PMA + deltamethrin on voltage-dependent
deactivation (ηdeactivation).
-80

-70

Test Potential (mV)
-60
-50

-40

-30

Treatment
(10-7M)
No Treatment

taudeactivation (ms)
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1.53 ± 0.16

1.66 ± 0.13

1.82 ± 0.10

2.02 ± 0.08

2.26 ± 0.08

2.56 ± 0.11

DMSO

1.81 ± 0.21

1.94 ± 0.19

2.10 ± 0.17

2.30 ± 0.16

2.55 ± 0.15

2.85 ± 0.17

Deltamethrin

1.55 ± 0.12

1.8 ± 0.14

2.09 ± 0.16

2.43 ± 0.19

2.83 ± 0.22

3.29 ± 0.26
♦(15)

4 min PMA +
deltamethrin

1.82 ± 0.17

1.99 ± 0.14

2.19 ± 0.10

2.42 ± 0.09

2.68 ± 0.14

2.98 ± 0.23

4α-PMA +
deltamethrin

0.98 ± 0.05

1.11 ± 0.05

1.27 ± 0.06
♦(-40)

1.57 ± 0.15
♦(-32)

1.67 ± 0.09
♦(-35)

1.80 ± 0.14
♦(-36)

1.86 ± 0.23

2.03 ± 0.21

2.23 ± 0.20

2.46 ± 0.19
◊(22)

2.74 ± 0.19
◊(21)

3.07 ± 0.19
◊(20)

Deltamethrin

1.52 ± 0.08

1.77 ± 0.1

2.06 ± 0.13

2.41 ± 0.17

2.81 ± 0.22

3.28 ± 0.28

10 min PMA +
deltamethrin

1.62 ± 0.17

1.89 ± 0.15

2.22 ± 0.14

2.61 ± 0.15

3.08 ± 0.21

3.65 ± 0.33

4α-PMA +
deltamethrin

0.98 ± 0.05

1.11 ± 0.05

1.28 ± 0.06
♦(-43)

1.57 ± 0.15
♦(-36)

1.67 ± 0.09
♦(-39)

1.80 ± 0.14
♦(-41)

DMSO
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An open diamond (◊) indicates significant difference from No Treatment. A closed diamond (♦) indicates significant
difference from DMSO. The values in parentheses (n) are percent increases or decreases. Significance was calculated
using Student’s T-test (P<0.05).
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an increase in neurotransmitter release and this cannot be achieved if neurotransmitter
release is dependent on channel activation alone. Thus, we can conclude that steady-state
activation is not the process by which deltamethrin alters CaV2.2 conductivity to increase
Ca2+-dependent neurotransmitter release.
Although not statistically significant, the rate of inactivation of unphosphorylated
CaV2.2 was slowed in the presence of deltamethrin (Table 6). This slowing of inactivation
is consistent with a previous report in which deltamethrin significantly slowing down the
rate of unphosphorylated CaV2.2 steady-state inactivation (Symington and Clark, 2005).
PKC-phosphorylated CaV2.2 inactivates faster in the presence of deltamethrin when
compared to the inactivation of unphosphorylated CaV2.2 in the presence of DMSO or
deltamethrin. This reduction in steady-state inactivation taus indicates that
phosphorylated CaV2.2 in the presence of deltamethrin takes less time to inactivate than
its unphosphorylated form and reduces Ba2+ influx. Because Ba2+ influx via CaV2.2
under phosphorylating conditions was increased, we expected a slowing of inactivation
may have occurred. However, we observed a slowing of inactivation in the presence of
deltamethrin only when CaV2.2 was not undergoing PMA-activated PKC
phosphorylation. When CaV2.2 is phosphorylated, we observed that deltamethrin
significantly increased the rate at which the channel inactivated under steady-state
depolarization. This finding is not consistent with increased Ca2+ influx necessary for
increased neurotransmitter release. We can conclude from this data that, like steady-state
activation, steady-state inactivation is not a process by which deltamethrin alters CaV2.2
conductance to increase Ca2+-dependent neurotransmitter release.
Steady-state deactivation in the presence of PMA + deltamethrin was significantly
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increased at both 4 and 10 min post treatments. An increase in deactivation taus indicates
a slower rate of open channels going to the closed state after the removal of steady-state
membrane depolarization signal (voltage change). This slower rate of closure means that
more Ba2+ is able to enter the cell via CaV2.2. Within the in vivo system, this increase in
Ba2+ (or Ca2+) influx results in the increased release of neurotransmitters. Furthermore,
the increase in neurotransmitter release is consistent with the symptoms observed in CSsyndrome as a result of deltamethrin poisoning (Hossain et al., 2004).
4α-PMA was used to test how deltamethrin would affect channel kinetics in the
presence of a phorbol ester that does not activate PKC-phosphorylation. When
deltamethrin was applied to 4α-PMA-treated CaV2.2, deactivation taus were reduced.
This reduction in deactivation taus means that 4α-PMA-treated CaV2.2 deactivates faster
than untreated CaV2.2 in the presence of deltamethrin. From this, we can conclude that
deltamethrin alters CaV2.2 deactivation kinetics under phosphorylating conditions and
that this change in deactivation gating kinetics increases Ba2+ influx. From this, we can
infer that the addition of deltamethrin to the in vivo system would result in increased
Ca2+-depedent neurotransmitter release that is consistent with CS-syndrome.
The increase in transient peak current and the slowing of deactivation rates of
phosphorylated CaV2.2, in the presence of deltamethrin, allow for increased Ba2+ influx
via phosphorylated CaV2.2. Within the in vivo system, the increase in Ba2+ (or Ca2+)
influx would translate into to increased neurotransmitter release, an effect observed
during deltamethrin poisoning.
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4.2.3 Voltage-dependent peak current
Deltamethrin treatment produced a significant decrease in maximal voltagedependent peak current at 10 min post treatment, which agrees with our steady-state data
and previously reported results that deltamethrin reduces steady state and voltagedependent peak current (Symington and Clark, 2005). The decrease in peak current
indicates that less Ba2+ is entering the cell via CaV2.2, which would translate into a
decrease in Ca2+ influx and a decrease in neurotransmitter release in the in vivo neuron.
We expected that the increase in peak current caused by PMA treatment would be
augmented by the presence of deltamethrin due to the observation that deltamethrin
increases neurotransmitter release from the in vivo neuron. We observed a significant
increase in voltage-dependent peak current of phosphorylated CaV2.2 in the presence of
deltamethrin. Within the in vivo neuron, this increase in peak current of phosphorylated
CaV2.2 in the presence of deltamethrin would mean that a significantly greater amount of
Ca2+ was flowing through the channel causing a significant increase in neurotransmitter
release.
In the presence of deltamethrin, the CaV2.2 mutant T422E underwent an increase
in maximal voltage-dependent peak current, which mimicked the effect of deltamethrin in
vivo (Symington et al., 2007a). We observed a similar increase in voltage-dependent peak
current of phosphorylated CaV2.2 in the presence of deltamethrin but the actual
phosphorylation pattern of CaV2.2 resulting from PMA-activated PKC phosphorylation
under experimental conditions is unknown. Using site-directed mutagenesis it was
determined that Ser425 is inhibitory when phosphorylated while the other four PKCdependent phosphorylation sites enhance Ba2+ influx (Fang et al., 2006). Our experiments
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do not control for which phosphorylation sites on CaV2.2 are phosphorylated and which
ones are not. Therefore using site-directed mutagenesis , we can “phosphorylate” the
channel at single or multiple sites by replacing the wild type amino acid with glutamate
and determine under which phosphorylation patterns we observe an increase in Ba2+
(Ca2+) influx in the presence of deltamethrin.
Maximal peak current in the presence of 4α-PMA + deltamethrin decreased at
both 4 and 10 min post treatment compared to No Treatment, 4α-PMA and PMA +
deltamethrin. This reduction in peak current means that Ba2+ influx through
unphosphorylated CaV2.2 in the presence is reduced. There was no significant difference
between CaV2.2 peak current in the presence of deltamethrin and CaV2.2 peak current in
the presence of 4α-PMA + deltamethrin indicating that the presence of the inactive
phorbol ester does not change the action of deltamethrin on the channel.
We propose that the difference between the effect of PMA + deltamethrin on
steady-state peak current versus voltage-dependent peak current may be due the multiple
step depolarizations that occur during the Activation Test Protocol used to obtain voltagedependent peak current versus the single step depolarization of the Transient Test
Protocol. As CaV2.2 undergoes multiple step depolarizations, the channels that are
opening at lower potentials are inactivating and remain in their unwilling state during
subsequent depolarization steps. The inactivation of these channels may be a mechanism
by which the maximal effect of deltamethrin on phosphorylated CaV2.2 during voltagedependent protocols was not observed.
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4.2.4 Voltage-dependent Gating Kinetics
Activation midpoint potentials (V50act) obtained in our study are consistent with
previous findings of enhanced neurotransmitter release. The V50act of unphosphorylated
CaV2.2 in the presence of deltamethrin underwent a hyperpolarizing shift at both 4 and 10
min post treatments. Phosphorylated CaV2.2 treated with deltamethrin had a significantly
greater hyperpolarizing shift in V50act compared to the V50act of the untreated
phosphorylated channels, indicating that the activation of phosphorylated CaV2.2
occurred at lower levels of depolarization. The increased sensitivity of deltamethrintreated PKC-phosphorylated CaV2.2 to smaller levels of membrane depolarizations is
consistent with increased Ba2+ influx within our heterologous expression system, and
enhanced neurotransmitter release within the in vivo system. In the presence of 4α-PMA
+ deltamethrin, the V50act underwent a depolarizing shift making the channel less likely to
activate when the membrane undergoes depolarization consistent with less Ba2+ (or Ca2+)
influx and less neurotransmitter release.
Deltamethrin treatment had no significant effect on inactivation midpoint
potentials (V50inact) of unphosphorylated CaV2.2. In the presence of PMA+ deltamethrin,
V50inact underwent a significant hyperpolarizing shift compared to the effects of DMSO
and deltamethrin treatments. This hyperpolarizing shift indicates that CaV2.2 will
inactivate at lower levels of depolarization thereby reducing the amount of Ba2+ influx.
The reduction of Ba2+ (or Ca2+) influx would translate into reduced neurotransmitter
release within the in vivo system. With the increase in neurotransmitter release observed
by Symington et al. (2007a), we expected to observe a depolarizing shift in V50inact, which
would indicate that CaV2.2 would require greater levels of depolarizations to inactivate.
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Instead, a significant hyperpolarizing shift similar to what we observed in the presence of
PMA was observed when phosphorylated CaV2.2 was treated with deltamethrin caused.
Deltamethrin also had no effect on voltage-dependent activation rate constants of
unphosphorylated CaV2.2 (ηactivation) following either the 4 or 10 min post treatments. The
increase in ηactivation at 10 min post treatment in the presence of PMA + deltamethrin
significantly increased at step potentials between -20 mV and 30 mV compared to DMSO
and indicates that phosphorylated CaV2.2 took more time to activate in the presence of
deltamethrin than the unphosphorylated channel. Also, the presence of deltamethrin on
the phosphorylated channel caused an increase in the length of time required to activate
the channel compared to the effect of deltamethrin on the unphosphorylated channel
between 10 mV and 30 mV. The increase in ηactivation of phosphorylated CaV2.2
corresponds with the increase of activation tau under steady-state deactivation but in both
cases, the increases in the time it takes for CaV2.2 to activate is not consistent with
increase Ba2+ influx. Thus, we would not expect an increase in activation taus to increase
Ca2+ influx and subsequent neurotransmitter release within the in vivo system. This result
is not consistent with increased Ca2+ via CaV2.2 resulting in increased neurotransmitter
release.
The effect of deltamethrin on 4α-PMA-treated CaV2.2 was a significant increase
in ηactivation constants at -30 mV, -20 mV and -10 mV at 10 min post treatment. At -30 mV
the ηactivation rate constant was nearly two times greater than the ηactivation rate constant of
DMSO. Under steady-state depolarization, activation taus remain unchanged in the
presence of 4α-PMA + deltamethrin , so the rate increase we observed under voltagedependent activation was unexpected and contradictory to what we observed under
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steady-state conditions especially considering previous reports of 4α-PMA being a nonactive form of PMA (Castagna et al., 1982; García-Ferreiro et al., 2001). The rate
increase would indicate, within the in vivo system, that CaV2.2 would take longer to
activate and that the amount of neurotransmitter that would eventually be released as a
result of Ca2+ influx once the channel opened would be reduced.
Under steady-state conditions, we observed that deltamethrin had no significant
effect on the deactivation tau of unphosphorylated CaV2.2. We observed, likewise, that
deltamethrin had almost no effect on voltage-dependent ηdeactivation, in the absence of PMA
the exception being an increase in the length of time required for the channel to close at 30 mV at 4 min post treatment. This means that within the in vivo system, the membrane
would have to undergo a large depolarization in the presence of deltamethrin in order for
there to be increased Ca2+ influx via unphosphorylated CaV2.2 followed by increased
neurotransmitter release.
The presence of deltamethrin on phosphorylated CaV2.2 under steady-state
conditions increased deactivation tau allowing for an increase in Ba2+ influx. There was
no such increase, however, in voltage-dependent ηdeactivation rate constants. This means
that in the presence of deltamethrin the amount of Ba2+ entering the cell via
phosphorylated CaV2.2 does not significantly differ from Ba2+ influx of our No
Treatment. We propose that the difference between the effect of PMA + deltamethrin on
steady-state deactivation taus versus voltage-dependent ηdeactivation may be due the multiple
step depolarizations undergone that occur the Activation Test Protocol used to obtain
ηdeactivation versus the single step depolarization of the Transient Test Protocol. As CaV2.2
undergoes multiple step depolarizations, the channels that are opening at lower potentials
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are inactivating and remain in their unwilling state during subsequent depolarization
steps. The inactivation of these channels may be a mechanism by which the maximal
effect of deltamethrin on phosphorylated CaV2.2 during voltage-dependent protocols was
not observed
The presence of 4α-PMA + deltamethrin had no significant effect on steady-state
deactivation taus at either 4 or 10 min post treatment, but caused significant decreases in
ηdeactivation rate constants at both time points compared to the DMSO control at
depolarization steps ranging from -60 mV to -30 mV. These decreases mean that the
presence of deltamethrin on a 4α-PMA-treated channel causes the channel to close an
average of 40% faster than it would in the presence of DMSO at step depolarizations at
or above -60 mV, and these faster rates reduce the amount of Ba2+ entering the via
CaV2.2. This faster rate of closure would translate as less Ca2+ uptake and less
neurotransmitter released, which does not cause the effects we observe in CS-syndrome.
These results differ from the steady-state data in that, under steady-state conditions, the
presence of 4α-PMA + deltamethrin had no significant effect on steady-state deactivation
gating kinetics.
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CHAPTER 5
SUMMARY AND FUTURE DIRECTIONS

Consistent with a previous study by Symington et al. (2005), we observed a
significant decrease in steady-state peak current when unphosphorylated CaV2.2 was
treated with deltamethrin. The decrease in steady-state peak current itself is inconsistent
with in vivo data, in which deltamethrin increased CaV2.2 currents and subsequent
neurotransmitter release (Table 13). We also observed a decrease in voltage-dependent
peak current of unphosphorylated CaV2.2 in the presence of deltamethrin. Although this
is consistent with work by Symington et al. (2005), it is not consistent with in vivo data in
which the presence of deltamethrin causes an increase in Ca2+ influx and subsequent
neurotransmitter release. When deltamethrin is added to PMA-activated, PKC-dependent
phosphorylated CaV2.2, steady-state and voltage-dependent peak current is significantly
increased, which is consistent with the in vivo data. Additionally, we observed an increase
in steady-state deactivation taus which is consistent with increased Ca2+ influx and
neurotransmitter release. Also, consistent with enhanced neurotransmitter release,
voltage-dependent activation midpoint potentials (V50act) of phosphorylated CaV2.2 in the
presence of deltamethrin underwent a hyperpolarizing shift. We have been able to
confirm previous reports which show that deltamethrin causes an increase in both steadystate and voltage-dependent peak current of phosphorylated CaV2.2, but we have also
reported novel changes in the kinetic profile of CaV2.2 (increased deactivation taus and
hyperpolarizing shift in the V50act) under the same conditions which support enhanced
Ca2+ influx and subsequent neurotransmitter release.
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Table 13. Summary of transient and voltage-dependent data endpoints of both
unphosphorylated and phosphorylated CaV2.2 modified by deltamethrin.
Unphosphorylated + ΔM
Consistent w/
Endpoint Neurotransmitter
Release?

Transient

Peak Current

Phosphorylated + ΔM
Consistent w/
Endpoint
Neurotransmitter
Release?
180.6 ± 15.3
♦(69) ■(107)
101.3 ± 3.8

Yes

Activation tau

87.4 ± 5.1 No
♦(-18)
100.9 ± 4.2 No

Inactivation tau

123.8 ± 10.7 No

No

Deactivation tau

125.6 ± 13.9 No

58.8 ± 6.5
♦(-53) ■(-52)
186.5 ± 42.5
♦*(79)

Peak Current

-1.00 ± 0.04 No

Yes

V50act

-1.83 ± 0.35 No

V50inact

-25.73 ± 2.47 No

-1.46 ± 0.19
◊(47) ♦(70)
■*(46)
-2.09 ± 0.29
●(-56)
-44.07 ± 3.45

No

Yes

Voltage-dependent

4 min

Yes
No

♦(-28) ■(-71)

Transient

Peak Current
Activation tau

72.6 ± 15.8 No
♦(-29)
107.7 ± 4.3 No

Inactivation tau

243.7 ± 40.8 No

Deactivation tau

129.6 ± 15.3 No

Peak Current

-0.87 ± 0.05 No

-1.08 ± 0.17

No

V50act

◊(-12%)
-3.44 ± 0.69 No

♦(21%)
-3.04 ± 0.61

Yes

V50inact

-21.21 ± 2.16 No

●(-117)
-44.69 ± 1.56

No

Voltage-dependent

10 min

185.8 ± 5.6
♦(82) ■(156)
123.6 ± 6.1
♦(14) ■(15)
92.8 ± 12.5
■(-62)
160.3 ± 17.2
♦*(54)

Yes
No
No
Yes

♦(-63) ■(-111)

An open diamond (◊) indicates significant difference from No Treatment. A closed
diamond (♦) indicates significant difference from DMSO. A square (■) indicates
significant difference from deltamethrin. A circle (●) indicates significant difference
from PMA. The values in parentheses (n) are percent increases or decreases. Significance
was calculated using Student’s T-test (P<0.05). Symbols followed by an asterisk (*)
indicate that the significance level was P < 0.1.
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Symington et al. (2005) reported a significant increase in steady-state inactivation
taus of deltamethrin-treated unphosphorylated CaV2.2 expressed in Xenopus oocytes
consistent with enhanced neurotransmitter release. PMA-activated PKC-dependent
phosphorylation of CaV2.2 enhanced steady-state peak current, activation and
deactivation taus but reduced steady-state inactivation taus (Table 13). We observed an
increase in steady-state inactivation tau but the change was not significant. Likewise,
when deltamethrin is added to the phosphorylated channel, inactivation tau is similarly
decreased in a manner that is inconsistent with in vivo that data showed deltamethrin,
enhances Ca2+ influx and neurotransmitter release. In the presence of deltamethrin, the
V50act of T422E underwent a depolarizing shift that was not consistent with our data
showing a hyperpolarizing shift in V50act of phosphorylated wild type CaV2.2 in the
presence of deltamethrin (Symington et al., 2007a). This difference between the T422E
mutant and our wild type CaV2.2 data indicates that the other phosphorylation sites on
CaV2.2 may contribute to Ca2+ influx in a way other than peak current. V50inact of
phosphorylated CaV2.2 in the presence of deltamethrin also underwent a hyperpolarizing
shift that was not consistent with increased Ba2+ (or Ca2+) influx and subsequent
neurotransmitter release. Increases in ηactivation or ηdeactivation would have been consistent
with enhanced neurotransmitter release, however, other than a significant increase in
ηdeactivation at 10 min post treatment and 30 mV, we did not observe any large changes
compared to the control (Table 14). It has been shown (Fang et al., 2006) that CaV2.2 has
five PKC-dependent phosphorylation sites of which, when phosphorylated, four are
agonistic to channel function (Thr422, Ser1757, Ser2108 and Ser2132) while the other
(Ser425) is antagonistic to channel function. Clearly, the current data supports the
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Table 14. Summary of voltage-dependent ηactivation and ηdeactivation data endpoints of both
unphosphorylated and phosphorylated CaV2.2modified by deltamethrin.

ηactivation

Voltage (mV)

ηactivation

ηdeactivation

4 min

Unphosphorylated + ΔM
Consistent w/
Endpoint Neurotransmitter
Release?

-30

4.80 ± 0.36 No

4.75 ± 0.39

No

-20

3.90 ± 0.25 No

3.96 ± 0.29

No

-10

3.17 ± 0.17 No

3.30 ± 0.21

No

0

2.58 ± 0.12 No

2.75 ± 0.15

No

10

2.10 ± 0.09 No

2.30 ± 0.11

No

20

1.72 ± 0.08 No

1.92 ± 0.09

No

30

1.40 ± 0.08
◊(10)

1.60 ± 0.07

No

-80
-70
-60
-50
-40
-30

1.55 ± 0.12
1.8 ± 0.14
2.09 ± 0.16
2.43 ± 0.19
2.83 ± 0.22
3.29 ± 0.26
♦(15)

1.82 ± 0.17
1.99 ± 0.14
2.19 ± 0.10
2.42 ± 0.09
2.68 ± 0.14
2.98 ± 0.23

No
No
No
No
No
No

-30

5.42 ± 0.32 No

5.07 ± 0.53

No

-20

4.34 ± 0.21 No

-10

3.47 ± 0.13

5.19 ± 0.99
♦(33)
4.11 ± 0.58
♦(28)
3.28 ± 0.3
♦(20)
2.64 ± 0.13
♦(23) ■(18)
2.14 ± 0.03
♦(21) ■(20)
1.75 ± 0.07
♦(20) ■(22)

No
No
No
No
No
Yes

No

No
No

0

2.78 ± 0.08 No

10

2.23 ± 0.06 No

20

1.79 ± 0.06 No

30

1.44 ± 0.06 No

-80

1.52 ± 0.08 No

1.62 ± 0.17

No

-70

1.77 ± 0.1

No
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An open diamond (◊) indicates significant difference from No Treatment. A closed
diamond (♦) indicates significant difference from DMSO. A square (■) indicates
significant difference from deltamethrin. The values in parentheses (n) are percent
increases or decreases. Significance was calculated using Student’s T-test (P<0.05).
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contention that T422 is not independent of the other phosphorylation sites.
The largest effect we observed on the unphosphorylated channel in the presence
of deltamethrin was the decrease in both steady-state and voltage-dependent peak current.
Since these results were in contrast to the effect of deltamethrin in vivo, they made clear
the possibility that post-translational modification occurring on CaV2.2 within the in vivo
system was either not present or not activated within the heterologous Xenopus oocyte
expression system. When deltamethrin was applied to phosphorylated CaV2.2 expressed
in Xenopus oocytes, we observed a reversal of deltamethrin inhibition of steady-state and
voltage-dependent peak current. The largest of these changes was the enhancement of
steady-state peak current, which remained significantly greater than did the DMSO or the
deltamethrin treatments at 4 and 10 min post treatment, and was unlike voltagedependent peak current which decreased over 10 min. The decrease in voltage-dependent
peak current could be due to those channels sensitive to low levels of membrane
depolarizations opening at those lower levels and being in the process of inactivating as
the membrane undergoes increasing levels of step depolarization. We were able to
replicate the steady-state peak current results of Symington et al. (2005) and Stea et al
(1995) in regards to the action of deltamethrin and phosphorylation on CaV2.2
respectively. When treating PKC-phosphorylated CaV2.2 with deltamethrin, we also
observed similar increases in voltage-dependent peak current compared to the T422E
experiments by Symington et al. (2007a) but we also obtained results that had yet to be
described.
We observed a novel increase in steady-state deactivation tau and a
hyperpolarizing shift in V50act of PKC-phosphorylated CaV2.2 in the presence of
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deltamethrin that was not evident when the T422E mutant (Symington et al., 2007a) was
treated with deltamethrin. The slowing of deactivation occurred when phosphorylated
CaV2.2 was treated with deltamethrin and this effect remained significant over 10 min.
This effect was not observed by Symington et al. (2007a) because unlike their T422E
mutant, our use of PMA-activated PKC-dependent phosphorylation had the potential to
phosphorylate some or all the PKC sites on CaV2.2, with one or more of them having the
potential to prolong steady-state deactivation tau. Lastly, we observed a significant shift
in V50act of phosphorylated CaV2.2 in the presence of deltamethrin. This could mean that
at least one of the PKC phosphorylation sites on CaV2.2 is responsible for making the
channel more sensitive to membrane depolarization. Again, these novel results indicate
that the simultaneous phosphorylation of multiple PKC-dependent phosphorylation sites
creates CaV2.2 phosphoforms that yield unique kinetic profiles.
Isoflurane, a volatile anesthetic, inhibits CaV2.2 steady-state and voltagedependent peak currents (Rajagopal et al., 2011) in much the same way deltamethrin
decreased steady-state and voltage-dependent peak current. Using Ser/Thr→Ala sitedirected mutagenesis, Rajagopal et al. (2011) created constructs that eliminated either the
stimulatory PKC-dependent phosphorylation site (Thr422, Ser1757, Ser2108 and S2132)
or the inhibitory PKC phosphorylation sites (Ser425) to determine the effect of
isofluorane currents. In the presence of isoflurane, modified CaV2.2 currents in which the
stimulatory sites were eliminated and Ser425 was left unchanged, were significantly
decreased compared to the wild type channel. A similar experiment using deltamethrin
may yield a similar result since isoflurane and deltamethrin have similar effects on the
wild type channel. Conversely, the elimination of only the inhibitory site Ser425 reversed
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the isoflurane inhibition of CaV2.2 currents and again, treating the same mutant construct
with deltamethrin may yield a similar response since the two compounds have similar
effects on the wild type channel. The next steps to take to determine the extent to which
the CaV2.2 stimulatory sites and the inhibitory site play a role in enhancement or
inhibition of CaV2.2 currents via would be to use several mutant constructs of the CaV2.2
to determine what effects the different phosphorylation states have on CaV2.2 currents
when exposed to deltamethrin. Fang et al. (2006) used several mutant constructs to
observe the effects of phosphorylation on CaV2.2. They observed wildly varying
responses to peak current when different PKC-dependent phosphorylation sites were
made “permanently phosphorylated” while others were left “permanently
unphosphorylated”. Two of the major observations Fang et al. (2006) made was that
residue Thr422 significantly increase peak current and residue Ser425 significantly
reduced peak current. The other three PKC phosphorylation sites were also stimulatory
but their effects were not nearly as significant as that of Thr422. In our experiments we
observed an enhancement of wild type CaV2.2 currents in the presence of deltamethrin
beyond the enhancement of peak current. Clearly phosphorylation of Thr422 is important
in enhancing CaV2.2 currents, but if it were the only important site, we would not have
observed changes in steady-state deactivation tau or V50act which both contribute to
enhanced Ca2+ influx and subsequent neurotransmitter release. In order to determine what
role each of the PKC phosphorylation sites play in kinetic profile of CaV2.2 in the
presence of deltamethrin we will have to implement an exhaustive site-directed
mutagenesis study similar to the one performed by Fang et al. (2006).
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APPENDIX
COMPOUNDS USED IN THIS STUDY

Deltmethrin

phorbol 12-myristate 13-acetate (PMA)

133

REFERENCES

Akopian, A.N., L. Sivilotti, and J.N. Wood. 1996. A tetrodotoxin-resistant voltage-gated
sodium channel expressed by sensory neurons. Nature. 379:257-262.
Aldridge, W.N., B. Clothier, P. Forshaw, M.K. Johnson, V.H. Parker, R.J. Price, D.N.
Skilleter, R.D. Verschoyle, and C. Stevens. 1978. The effect of DDT and the
pyrethroids cismethrin and decamethrin on the acetyl choline and cyclic
nucleotide content of rat brain. Biochemical Pharmacology. 27:1703-1706.
Alves, A.-M., S.B. Symington, S.H. Lee, and J.M. Clark. 2010. PKC-dependent
phosphorylations modify the action of deltamethrin on rat brain N-type (CaV2.2)
voltage-sensitive calcium channel. Pesticide Biochemistry and Physiology. 97:
101-108.
Armstrong, C.M. 1981. Sodium channels and gating currents. Physiol Rev. 61:644-683.
Augustine, G.J., M.P. Charlton, and S.J. Smith. 1987. Calcium action in synaptic
transmitter release. Annu Rev Neurosci. 10:633-693.
Barrett, C.F., and A.R. Rittenhouse. 2000. Modulation of N-type calcium channel activity
by G-proteins and protein kinase C. J Gen Physiol. 115:277-286.
Bourinet, E., F. Fournier, J. Nargeot, and P. Charnet. 1992. Endogenous Xenopus-oocyte
Ca-channels are regulated by protein kinases A and C. Federation of European
Biochemical Societies. 299:5-9.
Breckenridge, C.B., L. Holden, N. Sturgess, M. Weiner, L. Sheets, D. Sargent, D.M.
Soderlund, J.-S. Choi, S. Symington, J.M. Clark, S. Burr, and D. Ray. 2009.
Evidence for a separate mechanism of toxicity for the Type I and the Type II
pyrethroid insecticides. NeuroToxicology. 30:S17-S31.
Brooks, M.W., and J.M. Clark. 1987. Enhancement of norepinephrine release from rat
brain synaptosomes by alpha cyano pyrethroids. Pesticide Biochemistry and
Physiology. 28:127-139.

134

Castagna, M., Y. Takai, K. Kaibuchi, K Sano, U. Kikkawa, and Y. Nishizuka.1982. Direct
activation of calcium-activated, phospholipid-dependent protein kinase by tumorpromoting phorbol esters. The Journal of Biological Chemistry. 257:7847-7851.
Catterall, W. 1997. Modulation of sodium and calcium channels by protein
phosphorylation and G proteins. Adv Second Messenger Phosphoprotein Res.
31:159-181.
Catterall, W. 2000a. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev
Cell Dev Biol. 16:521-555.
Catterall, W.A. 2000b. From ionic currents to molecular mechanisms: the structure and
function of voltage-gated sodium channels. Neuron. 26:13-25.
Catterall, W.A., J. Striessnig, T.P. Snutch, and E. Perez-Reyes. 2003. International Union
of Pharmacology. XL. Compendium of Voltage-Gated Ion Channels: Calcium
Channels. Pharmacological Reviews. 55:579-581.
Choi, J.-S., and D.M. Soderlund. 2006. Structure-activity relationships for the action of
11 pyrethroid insecticides on rat NaV1.8 sodium channels expressed in Xenopus
oocytes. Toxicology and Applied Pharmacology. 211:233-244.
Clark, J., and M. Brooks. 1989. Role of ion channels and intraterminal calcium
homeostasis in the action of deltamethrin at presynaptic nerve terminals. Biochem
Pharmacol. 38:2233-2245.
Clark, J.M., S.J. Edman, S.R. Nagy, A. Canhoto, F. Hecht, and J. Van Houten. 1995.
Action of DDT and Pyrethroids on Calcium Channels in Paramecium tetraurelia.
J.M. Clark, editor. American Chemical Society. 591:173-190.
Cooper, C.B., M.I. Arnot, Z.P. Feng, S.E. Jarvis, J. Hamid, and G.W. Zamponi. 2000.
Cross-talk between G-protein and protein kinase C modulation of N-type calcium
channels is dependent on the G-protein beta subunit isoform. J Biol Chem.
275:40777-40781.
Corbalán-García, S., and J.C. Gómez-Fernández. 2006. Protein kinase C regulatory
domains: the art of decoding many different signals in membranes. Biochim
Biophys Acta. 1761:633-654.

135

Doering, C.J., A.E. Kisilevsky, Z.P. Feng, M.I. Arnot, J. Peloquin, J. Hamid, W. Barr, A.
Nirdosh, B. Simms, R.J. Winkfein, and G.W. Zamponi. 2004. A single G subunit
locus controls cross-talk between protein kinase C and G protein regulation of Ntype calcium channels. J Biol Chem. 279:29709-29717.
Drean, G., C. Leclerc, A.M. Duprat, and M. Moreau. 1995. Expression of L-type Ca2+
channel during early embryogenesis in Xenopus laevis. Int J Dev Biol. 39:10271032.
Eells, J.T., and M.L. Dubocovich. 1988. Pyrethroid insecticides evoke neurotransmitter
release from rabbit striatal slices. Journal of Pharmacology and Experimental
Therapeutics. 246:514-521.
Elliott, M., A.W. Farnham, N.F. Janes, P.H. Needham, and D.A. Pulman. 1974.
Insecticidally active conformations of pyrethroids. In G.K. Kohn, editor. American
Chemical Society, Washington, D.C. 80-91.
Fang, H., S. Patanavanich, S. Rajagopal, X. Yi, M.S. Gill, J.J. Sando, and G.L. Kamatchi.
2006. Inhibitory role of Ser-425 of the 1 2.2 subunit in the enhancement of
CaV2.2 currents by phorbol-12-myristate, 13-acetate. J Biol Chem. 281:2001120017.
Finkbeiner, S., and M.E. Greenberg. 1998. Ca2+ channel-regulated neuronal gene
expression. J Neurobiol. 37:171-189.
García-Ferreiro, R.E., E.O. Hernández-Ochoa, and D.E. García. 2001. Modulation of Ntype Ca2+ channel current kinetics by PMA in rat sympathetic neurons. Pflugers
Arch. 442:848-858.
Ginsburg, K., and T. Narahashi. 1993. Differential sensitivity of tetrodotoxin-sensitive
and tetrodotoxin-resistant sodium channels to the insecticide allethrin in rat dorsal
root ganglion neurons. Brain Res. 627:239-248.
Goldin, A. 1992. Maintenance of Xenopus laevis and oocyte injection. Methods Enzymol.
207:266-279.
Goldin, A.L., R.L. Barchi, J.H. Caldwell, F. Hofmann, J.R. Howe, J.C. Hunter, R.G.
Kallen, G. Mandel, M.H. Meisler, Y.B. Netter, M. Noda, M.M. Tamkun, S.G.
Waxman, J.N. Wood, and W.A. Catterall. 2000. Nomenclature of voltage-gated
sodium channels. Neuron. 28:365-368.
136

Hamid, J., D. Nelson, R. Spaetgens, S.J. Dubel, T.P. Snutch, and G.W. Zamponi. 1999.
Identification of an integration center for cross-talk between protein kinase C and
G protein modulation of N-type calcium channels. J Biol Chem. 274:6195-6202.
Hanlon, M.R., and B.A. Wallace. 2002. Structure and function of voltage-dependent ion
channel regulatory  subunits. Biochemistry. 41:2886-2894.
Hartzell, C., I. Putzier, and J. Arreola. 2005. Calcium-Activated Chloride Channels.
Annual Review of Physiology. 67:719-758.
Hildebrand, M.E., J.E. McRory, T.P. Snutch, and A. Stea. 2004. Mammalian voltagegated calcium channels are potently blocked by the pyrethroid insecticide
allethrin. J Pharmacol Exp Ther. 308:805-813.
Hodgkin, A.L., and A.F. Huxley. 1952. A quantitative description of membrane current
and its application to conduction and excitation in nerve. J Physiol. 117:500-544.
Hossain, M.M., T. Suzuki, I. Sato, T. Takewaki, K. Suzuki, and H. Kobayashi. 2004. The
modulatory effect of pyrethroids on acetylcholine release in the hippocampus of
freely moving rats. Neurotoxicology. 25:825-833.
Isom, L.L., K.S.D. Jongh, D.E. Patton, B.F.X. Reber, J. Offord, H. Charbonneau, K.
Walsh, A.L. Goldin, and W.A. Catterall. 1992. Primary Structure and Functional
Expression of the 1 Subunit of the Rat Brain Sodium Channel. Science. 256:839842.
Isom, L.L., D.S. Ragsdale, K.S. De Jongh, R.E. Westenbroek, B.F.X. Reber, T. Scheuer,
and W.A. Catterall. 1995. Structure and function of the 2 subunit of brain sodium
channels, a transmembrane glycoprotein with a CAM motif. Cell. 83:433-442.
Kass, R.S. 2004. Sodium Channel Inactivation Goes with the Flow. The Journal of
General Physiology. 124:7-8.
Kellenberger, S., T. Scheuer, and W.A. Catterall. 1996. Movement of the Na1 Channel
Inactivation Gate during Inactivation. The Journal of Biological Chemistry.
271:30971-30979.

137

Kostyuk, P.G., and R.E. Shirokov. 1989. Deactivation kinetics of different components of
calcium inward current in the membrane of mice sensory neurones. J Physiol.
409:343-355.
Li, D., F. Wang, M. Lai, Y. Chen, and J.F. Zhang. 2005. A protein phosphatase 2c-Ca2+
channel complex for dephosphorylation of neuronal Ca2+ channels phosphorylated
by protein kinase C. J Neurosci. 25:1914-1923.
Lin, Z., S. Haus, J. Edgerton, and D. Lipscombe. 1997. Identification of functionally
distinct isoforms of the N-type Ca2+ channel in rat sympathetic ganglia and brain.
Neuron. 18:153-166.
Liu, W.S., and C.A. Heckman. 1998. The Sevenfold Way of PKC Regulation. Cellular
Signaling. 10:529-542.
Maeno-Hikichi, Y., S. Chang, K. Matsumura, M. Lai, H. Lin, N. Nakagawa, S. Kuroda,
and J.F. Zhang. 2003. A PKC epsilon-ENH-channel complex specifically
modulates N-type Ca2+ channels. Nat Neurosci. 6:468-475.
Martinez-Pinna, J., E.M. McLachlan, and R. Gallego. 2000. Distinct mechanisms for
activation of Cl- and K+currents by Ca2+ from different sources in mouse
sympathetic neurones. Journal of Physiology.249â€”264.
Mosior, M., and A.C. Newton. 1996. Calcium-Independent Binding to Interfacial Phorbol
Esters Causes Protein Kinase C To Associate with Membranes in the Absence of
Acidic Lipidsâ€ 35:1612-1623.
Narahashi, T. 1992. Nerve Membrane Na+ Channels as targets of insecticides. Trends in
Pharmacological Sciences. 13:234-241.
Narahashi, T., A. Tsunoo, and M. Yoshii. 1987. Characterization of two types of calcium
channels in mouse neuroblastoma cells. J Physiol (Lond). 383:231-249.
Narahashi, T., and T. Yamasaki. 1960. Mechanism of Increase in Negative After-Potential
by Dicophanum (DDT) in the Giant Axons of the Cockroach. Journal of
Physiology. 152:122-140.

138

Neal, A.P., Y. Yuan, and W.D. Atchinson. 2010. Allethrin Differentially Modulates
Voltage-Gated Calcium Channel Subtypes in Rat PC12 Cells. Toxicological
Sciences. 116:604-613.
Newton, A.C. 2001. Protein kinase C: structural and spatial regulation by
phosphorylation, cofactors, and macromolecular interactions. Chem Rev.
101:2353-2364.
Nichols, R.A., J.W. Haycock, J.K. Wang, and P. Greengard. 1987. Phorbol ester
enhancement of neurotransmitter release from rat brain synaptosomes. J
Neurochem. 48:615-621.
Nishizuka, Y. 1992. Intracellular signaling by hydrolysis of phospholipids and activation
of protein kinase C. Science. 258:607-614.
Ogata, N., and H. Tatebayashi. 1993. Kinetic analysis of two types of Na+ channels in rat
dorsal root ganglia. J Physiol. 466:9-37.
Perez-Reyes, E. 2003. Molecular Physiology of Low-Voltage-Activated T-Type Calcium
Channels. Physiol Rev. 83:117-161.
Rajagopal, S., H. Fang, C. Lynch Iii, J.J. Sando, and G.L. Kamatchi. 2011. Effects of
isoflurane on the expressed Cav2.2 currents in Xenopus oocytes depend on the
activation of protein kinase C [delta] and its phosphorylation sites in the
Cav2.2[alpha]1 subunits. Neuroscience. 182:232-240.
Ray, D.E., and J.R. Fry. 2006. A reassessment of the neurotoxicity of pyrethroid
insecticides. Pharmacology and Therapeutics. 111:174-193.
Rossie, S. 1999. Regulation of voltage-sensitive sodium and calcium channels by
phosphorylation. Adv Second Messenger Phosphoprotein Res. 33:23-48.
Roy, M.L., and T. Narahashi. 1992. Differential Properties of Tetrodotoxin-sensitive and
Tetrodotoxin-resistant Sodium Channels in Rat Dorsal Root Ganglion Neurons.
The Journal of Neuroscience. 12:2104-2111.

139

Shafer, T.J., and D.A. Meyer. 2004. Effects of pyrethroids on voltage-sensitive calcium
channels: a critical evaluation of strengths, weaknesses, data needs, and
relationship to assessment of cumulative neurotoxicity. Toxicol Appl Pharmacol.
196:303-318.
Shafer, T.J., D.A. Meyer, and K.M. Crofton. 2005. Developmental Neurotoxicity of
Pyrethroid Insecticides: Critical Review and Future Research Needs.
Environmental Health Perspectives. 113:123-136.
Shih, T.M., R.D. Smith, L. Toro, and A.L. Goldin. 1998. High-level expression and
detection of ion channels in Xenopus oocytes. Methods Enzymol. 293:529-556.
Soderlund, D.M., and J.R. Bloomquist. 1989. Neurotoxic actions of pyrethroid
insecticides. Annu Rev Entomol. 34:77-96.
Soderlund, D.M., J.M. Clark, L.P. Sheets, L.S. Mullin, V.J. Piccirillo, D. Sargent, J.T.
Stevens, and M.L. Weiner. 2002. Mechanisms of pyrethroid neurotoxicity:
implications for cumulative risk assessment. Toxicology. 171:3-59.
Soderlund, D.M., and S.H. Lee. 2001. Point Mutations in Homology Domain II Modify
the Sensitivity of Rat Nav1.8 Sodium Channels to the Pyrethroid Insecticide
Cismethrin. NeuroToxicology. 22:755-765.
Stea, A., T.W. Soong, and T.P. Snutch. 1995. Determinants of PKC-dependent modulation
of a family of neuronal calcium channels. Neuron. 15:929-940.
Swanson, R., and K. Folander. 1992. In vitro synthesis of RNA for expression of ion
channels in Xenopus oocytes. Methods Enzymol. 207:310-319.
Swartz, K.J. 1993. Modulation of Ca2+ channels by protein kinase C in rat central and
peripheral neurons: disruption of G protein-mediated inhibition. Neuron. 11:305320.
Swartz, K.J., A. Merritt, B.P. Bean, and D.M. Lovinger. 1993. Protein kinase C modulates
glutamate receptor inhibition of Ca2+ channels and synaptic transmission. Nature.
361:165-168.

140

Symington, S., R. Frisbie, H. Kim, and J. Clark. 2007a. Mutation of Threonine 422 to
Glutamic Acid Mimics the Phosphorylation State and Alters the Action of
Deltamethrin on CaV2.2. In. Pesticide Biochemistry and Physiology. 312-320.
Symington, S., A. Zhang, and J. Clark. 1999a. The action of pyrethroids on the voltagesensitive calcium channel of Paramecium tetraurelia. In. Pesticide Science. 10351037.
Symington, S., A. Zhang, W. Karstens, J. Van Houten, and J. Clark. 1999b.
Characterization of pyrethroid action on ciliary calcium channels in Paramecium
tetraurelia. In. Pesticide Biochemistry and Physiology. 181-193.
Symington, S.B., and J.M. Clark. 2005. Action of deltamethrin on N-type (CaV2.2)
voltage-sensitive calcium channels in rat brain. In.
Symington, S.B., R.K. Frisbie, K.D. Lu, and J. Marshall Clark. 2007b. Action of
cismethrin and deltamethrin on functional attributes of isolated presynaptic nerve
terminals from rat brain. Pesticide Biochemistry and Physiology. 87:172-181.
Tan, J., and D.M. Soderlund. 2009. Human and rat NaV1.3 voltage-gated sodium
channels differ in inactivation properties and sensitivity to the pyrethroid
insecticide tefluthrin. NeuroToxicology. 30:81-89.
Vais, H., S. Atkinson, N. Eldursi, A.L. Devonshire, M.S. Williamson, and P.N.R.
Usherwood. 2000. A single amino acid change makes a rat neuronal sodium
channel highly sensitive to pyrethroid insecticides. FEBS Letters. 470:135-138.
Vance, C.L., C.M. Begg, W.L. Lee, H. Haase, T.D. Copeland, and M.W. McEnery. 1998.
Differential expression and association of calcium channel 1B and  subunits
during rat brain ontogeny. J Biol Chem. 273:14495-14502.
Wang, S.-Y., and G.K. Wang. 2003. Voltage-gated sodium channels as primary targets of
diverse lipid-soluble neurotoxins. 15:151-159.
Weiner, M.L., M. Nemec, L. Sheets, D. Sargent, and C. Breckenridge. 2009. Comparative
functional observational battery study of twelve commercial pyrethroid
insecticides in male rats following acute oral exposure. NeuroToxicology. 30:S1S16.

141

Xiao, H., X.-C. Zhang, L. Zhang, X.-Q. Dai, W. Gong, J. Cheng, R. Gao, and X. Wang.
2006. Fenvalerate modifies T-type Ca2+ channels in mouse spermatogenic cells.
Reproductive Toxicology. 21:48-53.
Xu, Y.F., S.J. Hewett, and W.D. Atchison. 1998. Passive Transfer of Lambert-Eaton
Myasthenic Syndrome Induces Dihydropyridine Sensitivity of ICa in Mouse Motor
Nerve Terminals. Journal of Neurophysiology. 80:1056-1069.
Yoshii, M. 1985. Effects of pyrethroids and veratridine on two types of calcium channels
in neuroblastoma cells. Society for Neuroscience Abstracts. 11:158.159.
Yu, F.H., and W.A. Catterall. 2003. Overview of the voltage-gated sodium channel
family. Genome Biology. 4:207.
Zamponi, G.W., E. Bourinet, D. Nelson, J. Nargeot, and T.P. Snutch. 1997. Crosstalk
between G proteins and protein kinase C mediated by the calcium channel 1
subunit. Nature. 385:442-446.
Zhu, Y., and S. Ikeda. 1994. Modulation of Ca2+-channel currents by protein kinase C in
adult rat sympathetic neurons. Journal of Neurophysiology. 72:1549-1560.

142

